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ABSTRACT 
Diabetes Mellitus is characterized by chronically elevated blood glucose levels, 
hyperglycaemia. Consistent adherence to appropriate glucose-lowering drug therapy is 
fundamental to prevent disease progression, diabetes-related complications and premature 
death. If patients do not dispense, do not take their medication, or if the drugs are not 
prescribed according to evidence-based medicine, the consequences may be serious. The 
purpose of this thesis was to study acute consequences of inadequate use of glucose-lowering 
drugs, and its associated risk factors.  
In Study I the impact of symptomatic hypoglycaemia on medication adherence, patient 
satisfaction with treatment, and glycaemic control was studied in patients with type 2 diabetes 
treated with metformin and SU. The main finding was that adherence was negatively 
associated with the severity of the experienced hypoglycaemic symptoms. Despite poorer 
adherence to glucose-lowering drugs, the group with more severe hypoglycaemia showed 
better glycaemic control compared to the group with milder symptoms. The results suggest 
that glycaemic control is achieved at the expense of symptoms of hypoglycaemia in patients 
treated with metformin and SU. Dissatisfaction with medicine and barriers to medication 
adherence were more likely among patients with more severe hypoglycaemia. The study 
shows that only 40 % of the patients treated with metformin and SU in a primary care setting 
achieved the HbA1c target. Hypoglycaemia seems to refrain both patients and physicians 
from adherence to the best possible use of glucose lowering drugs. 
In Study II, potential risk factors associated with fatal hyperglycaemia were studied in 
deceased individuals with dispensed glucose-lowering drugs from pharmacies and their 
matched living controls. A significantly larger proportion of those who died due to 
hyperglycaemia lived in single households, had a history of psychiatric illness, was treated 
with insulin and had known alcohol abuse as compared to controls. Highly elevated glucose 
levels (HbA1c ≥75 mmol / mol) at the last health care visit were significantly associated with 
an increased risk of fatal hyperglycaemia. A larger proportion of the deceased had 
unsatisfactory refill adherence of glucose-lowering drugs. In addition, we found that 48 
(15%) of the deceased individuals were undiagnosed. 
In Study III, reference concentrations for fatal metformin intoxications and associated risk 
factors were studied in a nationwide group of deceased, with detected metformin in the blood. 
The extensive information from forensic autopsy results and police reports was supplemented 
with detailed information on medical history, dispensed drugs and diabetes-related variables 
from several linked national registries. The verified reference concentrations for metformin 
may be particularly useful in cases where complementary information is missing. Metformin 
intoxication was intentional only in eight cases (23%), suggesting that high drug 
concentrations in the post-mortem context may not always be due to an acute high intake of 
the drug. The study shows that the most common risk factor in metformin intoxications was 
contraindications to the use of metformin, including; alcohol abuse and renal dysfunction. In 
this study, less than half of the study population achieved the recommended HbA1c target, 
based on the treatment goals listed in the national guidelines. 
Conclusions: The results confirm that high blood glucose levels need clinical attention, as an 
indication of inadequate use of glucose lowering drugs, which may lead to serious 
consequences. Further, unsatisfied refill adherence of GLD is associated with fatal 
hyperglycaemia in individuals with diabetes. Increased understanding of patient-reported 
outcome measures could improve the care of individuals with diabetes mellitus. The results 
also indicate that socio-economic and psychosocial factors, e.g. single households and / or 
alcohol abuse, should be noted as they may be important risk factors that seemingly are 
equally important as traditional risk factors. The included studies collectively indicate that 
both patient behaviour and the physician’s clinical inertia represent crucial barriers to 
appropriate use of glucose lowering drugs.  
Finally, by linking forensic toxicology data with national registries, we have revealed results 
of importance to improve adequate use of glucose lowering drugs and which may contribute 
to prevent patients from severe consequences due to inadequate use of glucose lowering 
drugs. This thesis demonstrates a public health-oriented application of medico-legal autopsies 
results, beyond their immediate and isolated use in forensic medicine. 
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1 POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ SVENSKA 
Diabetes mellitus är en av världens vanligaste och snabbast ökande kroniska sjukdomar. 
Sjukdomen kännetecknas av kroniskt förhöjda blodglukosvärden, hyperglykemi. 
Kontinuerlig följsamhet till lämplig glukossänkande läkemedelsbehandling i syfte att uppnå 
glukoskontroll är en grundläggande del av behandlingen för att förhindra 
sjukdomsprogression, diabetesrelaterade komplikationer och prematur död. Men om 
patienten inte hämtar ut, inte tar sina läkemedel eller om läkemedlen inte förskrivs enligt 
etablerad praxis kan konsekvenserna bli förödande. Syftet med denna avhandling har varit att 
studera konsekvenser av inadekvat användning av glukossänkande läkemedel, och dess 
associerade riskfaktorer. De inkluderade studierna fokuserar på akuta komplikationer som 
kan vara associerade med inadekvat användning av glukossänkande läkemedelsbehandling, 
såsom symptomatisk hypoglykemi, dödlig hyperglykemi och metformin-förgiftning med 
dödlig utgång. 
I studie I undersöktes om symptomatisk hypoglykemi påverkar följsamheten till ordinerad 
glukossänkande läkemedelsbehandling, patientens nöjdhet med behandlingen och den 
glykemiska kontrollen hos patienter med typ 2 diabetes. En ökande svårighetsgrad av de 
upplevda hypoglykemierna var associerad med en försämrad följsamhet till den 
glukossänkande läkemedelsbehandlingen. Trots sämre följsamhet till glukossänkande 
läkemedel var gruppen med mer besvärande hypoglykemi förknippad med bättre glykemisk 
kontroll. Resultaten tyder på att glykemisk kontroll uppnåddes på bekostnad av biverkningar, 
såsom symptomatisk hypoglykemi, hos patienter som behandlas med metformin och SU. 
Patientrapporterade utfallsmått visade att en större andel av de med mer besvärande 
hypoglykemi var mera missnöjda med sin glukossänkande behandling samt uppgav fler 
barriärer för god följsamhet till läkemedelsbehandlingen jämfört med de som upplevde 
mindre besvärande symptom. Studien åskådliggör även att endast 40 % av patienterna som 
behandlades med metformin och SU uppnådde målet för HbA1c baserat på de 
behandlingsmål som angavs i de svenska nationella riktlinjerna.  
I studie II undersöktes möjliga riskfaktorer associerade med dödlig hyperglykemi hos avlidna 
individer som hämtat ut glukossänkande läkemedel på apotek och dess matchade levande 
kontroller, slumpmässigt utvalda i läkemedelsregistret. En signifikant större andel av de som 
avled i dödlig hyperglykemi levde i ensamhushåll, behandlades med insulin och hade känt 
alkoholmissbruk jämfört med kontrollerna. Kraftigt förhöjda glukosvärden (HbA1c ≥75 
mmol/mol) vid senaste sjukvårdsbesöket var associerat med en ökad risk att dö i 
hyperglykemi. De som dog av hyperglykemi uppvisade i större grad perioder (> 125 dagar) 
då de saknade uthämtade glukossänkande läkemedel än kontrollerna. Polisrapporterna 
bekräftade att ca hälften av de avlidna inte hade några glukossänkande läkemedel på platsen 
vid dödstillfället. Dessutom fann vi att 48 (15 %) av de avlidna individerna var 
odiagnostiserade och hade aldrig hämtat ut glukossänkande läkemedel på apotek. Resultatet 
bekräftar att många individer med typ 2 diabetes förmodligen är odiagnostiserade och att fatal 
hyperglykemi kan vara den första manifestationen av diabetes. 
I studie III studerades riskfaktorer associerade med dödlig metformin-förgiftning i en 
rikstäckande grupp avlidna individer med metformin i blodet. Koncentrationen av metformin 
i lårblod var signifikant högre hos dem som dött av metformin-förgiftning jämfört med 
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kontrollerna. Den omfattande informationen från medicinska obduktionsresultat och 
polisrapporter kompletterades med betydande information om sjukdomshistoria, uthämtade 
läkemedel och diabetesrelaterade variabler från flera länkade nationella register. De 
verifierade referenskoncentrationerna för metformin kan komma att bli särskilt användbara i 
fall där komplementär information saknas. I endast åtta fall (23 %) var metformin-
förgiftningen avsiktlig, vilket talar för att de flesta dödsfallen snarare orsakats av en 
ackumulering av läkemedlet över tid. Studien visar att den vanligaste riskfaktorn vid 
metformin-förgiftning var kontraindikationer för användningen av metformin, kvantifierad 
som; alkoholmissbruk (77,3%), nedsatt njurfunktion (40,9%), svår pågående infektion 
(27,7%) eller intorkning (31,6%). I den här studien uppnådde mindre än hälften av 
studiepopulationen det rekommenderade HbA1c-målet enligt den sista registreringen i det 
nationella diabetesregistret. 
Sammanfattande slutsats: Ett led i att förbättra omhändertagandet av individer med diabetes 
kan vara att uppmärksamma inadekvat glukossänkande behandling för att möjliggöra 
optimering av behandlingen. Avhandlingen visar att konsekvenserna av inadekvat 
användning av glukossänkande läkemedel är mångfacetterade. Alla tre studierna i 
avhandlingen visar dock att den glykemiska kontrollen var otillräcklig hos en stor andel av de 
som drabbades av akuta allvarliga komplikationer associerade med inadekvat 
läkemedelsanvändning. Studie II åskådliggör att bristande uttagsföljsamhet är associerat med 
dödlig hyperglykemi hos individer med diabetes. Resultaten bekräftar att höga 
blodglukosvärden borde uppmärksammas mer i klinisk vardag eftersom det kan vara tecken 
på non-adherence eller annan inadekvat läkemedelsanvändning, som kan leda till allvarliga 
konsekvenser och i värsta fall dödlig hyperglykemi. Patienter som rapporterar missnöje med 
sin behandling bör tas på allvar då missnöjet kan vara associerat med låg följsamhet och ökad 
risk för avbruten behandling med allvarliga konsekvenser för patienten, vården och samhället. 
Ökad förståelse för patient-rapporterade utfallsmått skulle kunna förbättra omhändertagandet 
av individer med diabetes mellitus. Resultaten från studie II och III indikerar dessutom att 
socioekonomiska och psykosociala faktorer, t.ex. ensamhushåll och/eller med 
alkoholmissbruk, borde uppmärksammas då de kan vara viktiga riskfaktorer som åsidosätts 
för mer traditionella riskfaktorer. Samtliga studier i avhandlingen pekar på att både patientens 
och sjukvårdspersonalens handlande utgör viktiga barriärer för att uppnå god följsamhet till 
lämplig glukossänkande läkemedelsbehandling.  
Slutligen visar avhandlingen värdet av medicinska/rättskemiska undersökningsresultat, utöver 
deras omedelbara och isolerade användning i rättsmedicin. Studiernas resultat kan vara av 
värde för framtida forskning för att studera lämpliga interventioner för att förbättra 
användningen av glukossänkande läkemedel i de identifierade riskgrupperna. 
 
 
  3 
2 INTRODUCTION 
Pharmaceutical drugs are of great benefit to patients to cure and relieve symptoms, delay 
complications or prevent premature death. However, medicines do not work if they are not 
taken or they may have negative consequences if not used according to evidence-based 
medicine. Findings collectively suggest that inadequate use of medications, including poor 
adherence and non-persistence with prescribed treatment regimens, reduces the effectiveness 
of medicine which increases morbidity and premature death, as well as increasing healthcare 
expenditures [1-4]. Adherence to appropriate prescribed medication helps patients stay 
healthy and correlates with a better quality of life as well as reduced cost for society [5-8]. 
Nevertheless, physicians should not assume that patients fully adhere to treatment regimens 
even if the consequences of non-adherence may be harmful. In view of that, physicians and 
other healthcare providers do not have sufficient control over the effectiveness of the 
prescribed treatment regimens. Several studies have shown that there are in general more 
adherence issues in long-term treatment plans regarding asymptomatic chronic diseases such 
as diabetes mellitus and those prescribed preventive medicine, than in treatment for acute 
diseases [8-10].  
The global prevalence of diabetes mellitus is on the rise and uncontrolled diabetes is a 
common cause of death; in 2015 diabetes caused approximately 5 million deaths globally 
[11]. Patients with diabetes are characterised by chronic hyperglycaemia. Accordingly, 
adequate management of glucose-lowering drugs (GLD) with regular adherence to medicine 
is crucial to prevent disease progression, diabetes-related complications and delay premature 
death. However, several systematic reviews over recent years mutually highlight non-
adherence to GLD as a prominent and ongoing serious problem [12-16]. Besides, 
approximately 600 individuals die each year in Sweden due to the consequences of 
intentional or accidental inadequate use of pharmaceutical drugs [17]. The World Health 
Organization has previously stressed that focusing on improvement of adherence to medicine 
could add more value to patients, society and the global wellbeing than any new medical 
discovery [8].  
The overall rationale behind this thesis is that inadequate use of medicine, including poor 
adherence, causes serious consequences for patients and for public health and society. This 
thesis focuses on non-adherence to GLD, since diabetes mellitus is a common chronic disease 
where non-adherence could result in serious and even life-threatening consequences for 
affected patients [18-20]. Further, the use of GLD in Sweden has escalated over recent years; 
the underlying explanations are probably an ageing population and earlier initiation of 
treatment, which calls for an increased awareness of inadequate use of GLD [21-24].  
Medication non-adherence may be considered as a modifiable disorder. However, most 
healthcare providers are not aware of the magnitude of the problem and usually not skilled to 
identify or handle medication non-adherence. The full benefit of treatment can only be 
achieved if the patient is diagnosed at the right time, treated with the right dose, with an 
effective drug with respect to the diagnosis and if patients follow prescribed treatment 
regimens reasonably carefully. Therefore, both patient behaviour and the physician’s clinical 
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inertia may represent possible barriers to adequate use of medicine. Considering the large 
amount of GLD that are available, understanding and addressing patient adherence problems 
and the physician’s clinical inertia are important to optimise treatment with pharmaceuticals 
and improve glucose control and the patient’s health outcomes.  
This thesis aims to reveal information that may lead to awareness and better understanding of 
the factors behind inadequate use of medicine to effectively optimise the use of GLD and 
improve the patient’s health outcomes. 
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3 BACKROUND 
3.1 DIABETES 
3.1.1 Epidemiology  
Diabetes mellitus is one of the most common and fastest growing chronic diseases in the 
world. The WHO reports that 422 million adults were diagnosed with diabetes in 2014 
compared to 108 million in 1980 [25]. The prevalence of diabetes has more than doubled 
over recent decades and it has been estimate that 592 million individuals (10%) of the total 
adult population will suffer from diabetes by 2035 [26]. Diabetes type 2 (T2DM) is the most 
common form, accounting for 85-95% of all cases. This form of diabetes may remain 
undetected for many years, adding a massive number of people living with undiagnosed 
T2DM [26, 27]. The largest increase in T2DM is perceived in low- and middle-income 
countries and the increase in incidence of T2DM is probably due to unhealthy lifestyle 
factors. However, western countries, including Sweden, are experiencing a plateau in the 
incidence of T2DM [25].   
Prevalence of diabetes is apparently lower in Scandinavia than other countries [26]. The 
prevalence of diabetes mellitus in Sweden is approximately 4-6.8%, with a very high 
proportion of T2DM (85-90%) [23, 28-30]. The prevalence of diabetes in a population is 
strongly dependent on age. In Sweden almost 20% of individuals 80 years of age or older are 
diagnosed with diabetes [23]. Furthermore, studies consistently report a larger proportion of 
men versus women with diabetes [21-23, 29, 31]. The prevalence of adults with T2DM 
treated with GLD in Sweden has increased in recent years; the underlying explanations are 
probably an ageing population and earlier initiation of treatment [23, 30]. The overall 
incidence seems to be stable but even when assuming constant incidence, Anderson et al. 
estimate prevalence of diabetes to be 10.4% by 2050 in Sweden [29].  
To conclude, diabetes mellitus is expected to become one of the most common health 
problems in Sweden and more than half a million people will be treated with GLD in the near 
future. This doctoral thesis aims to evaluate consequences of inadequate use of GLD and 
contribute to a better understanding and awareness of risk factors associated with these 
consequences to improve future outcomes. 
3.1.2 Classification 
Diabetes mellitus is a cluster of complex metabolic diseases with raised blood glucose levels 
due to impairment in insulin secretory function or where cells do not respond accurately to 
the insulin produced. The classification is based on older recommendations from World 
Health Organization (WHO) but there are also and updated versions from American Diabetes 
Association ADA [32, 33]. According to current recommendations, most individuals with 
diabetes can be classified into the following general categories based on etiology [32]. 
Type 1 diabetes accounts for the vast majority of diabetes in children but represents only 5–
10% of the total population with diabetes. T1DM usually starts early in life, although an 
individual can develop the disease at any age. This type of the disease is a multifactorial 
disease with genetic predisposition and environmental factors that trigger an autoimmune 
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impairment of the pancreas, where the β-cells destruction leads to a total stop in insulin 
production. Latent adult autoimmune diabetes, LADA is a slow progressing type of type 1 
diabetes. Patients resemble T2DM with conserved β-cell function, without the urgent need for 
insulin therapy but with the presence of autoantibodies directed to insulin-producing cells 
[34]. 
Type 2 diabetes mellitus (T2DM) is the most prevalent form of diabetes. T2DM is a 
progressive disease with worsening hyperglycaemia over time, due to a progressive loss of 
insulin secretion as well as insulin resistance. Studies have shown that a genetic predisposition 
increases the risk in the presence of environmental factors such as high calorie nutrition, an 
inactive lifestyle and use of tobacco [35, 36]. During earlier stages, the symptoms of 
hyperglycaemia could be asymptomatic or not severe enough to alert the patient [37]. 
Nevertheless, these patients are at increased risk of developing severe diabetes-related 
complications. 
Gestational diabetes mellitus (GDM) is a temporary disease diagnosed in the second or third 
trimester of pregnancy. It is important to regularly monitor glucose levels among women with 
previous gestational diabetes, since they have an increased risk of developing type 2 diabetes 
compared with women with normoglycemic pregnancy [38]. 
Specific types of diabetes due to other causes:  
• Monogenic diabetes syndrome (MODY) is a form of neonatal diabetes with a genetic 
defect of β-cells function; a minor fragment of patients with diabetes (<5%) 
• Cystic fibrosis–related diabetes (CFRD) is a comorbidity in people with cystic fibrosis, 
with insulin deficiency as the primary defect 
• Drug- or chemical-induced diabetes  
• New-onset diabetes after transplantation (NODAT); in individuals who develop 
diabetes post organ transplantation 
• Pancreatic disease including surgical removal 
• Endocrinopathies (Cushing´s syndrome) 
• Rare genetic disorders (e.g. Klinefelter´s syndrome) 
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3.1.3 Glucose metabolism   
Energy is required for the functioning of the organs in the body. Most tissues can use fat or 
protein as an energy source, but the brain can only use glucose. Accordingly, carbohydrates, 
mainly available as glucose, are the primary energy source. The concentration of glucose in 
plasma should normally be lower than 100 to 109 mg per decilitre (5.55 to 6.05 mmol/L) in 
healthy individuals [32]. In the case of increased concentrations of glucose, liver and muscle 
cells convert excess glucose to glycogen. The liver is a central storage site for glycogen [39]. 
Glycogen is mobilised and broken down to glucose by gluconeogenesis when the blood 
glucose concentration is low, or the cells need energy. When oxygen is available, glucose is 
metabolized to substantial amount of energy and carbon dioxide and water. In the absence of 
oxygen, the metabolism becomes incomplete, less energy is produced and lactic acid is 
formed. After food intake insulin is released via the incretin effect, due to the increased blood 
sugar level. The uptake of glucose in the skeletal muscle cells, adipose tissue and the release 
of glucose from glycogen is regulated by insulin. Insulin and glucagon work synergistically 
to keep blood glucose concentrations normal and they are secreted from the endocrine tissue 
in the pancreas [39]. The endocrine tissue is grouped in the islets of Langerhans and consists 
of different cell types with different functions. The α-cells produce glucagon and β-cells 
produce proinsulin, which is converted to insulin in the circulation [40, 41]. 
3.1.4 Complications  
Poorly controlled diabetes has dreadful consequences for patients, clinicians and society. 
There are different types of diabetes-related complications, acute and chronic conditions. In 
this thesis focus is on the acute complications, including diabetes coma, hyperglycaemia, 
hypoglycaemia, and intoxications due to GLD. Further, chronic complications are divided 
into micro- and macrovascular complications, with a wide range of different conditions. 
Microvascular complications are complications of the small blood vessels of the body and 
include neuropathy, retinopathy and nephropathy, which may lead to foot ulcers, limb 
amputation, blindness and renal failure. Macrovascular complications are complications of 
the large blood vessels of the body, including the coronary arteries, the aorta, and the sizeable 
arteries in the brain and in the limbs. The most important macrovascular complication is 
cardiovascular disease (CVD), including stroke and myocardial infarction (MI). The ultimate 
goal of type 2 diabetes management is to prevent or delay the onset of diabetes-related micro- 
and macrovascular complications. The main focus of treatment lies in controlling HbA1c, but 
control of other cardiovascular risk factors such as obesity, hypertension and dyslipidaemia 
are also important. Several landmark studies have showed that uncontrolled blood glucose is 
related to disease progression and microvascular complications, though the impact of 
hyperglycaemia on macrovascular complications still remains slightly vague [42-45]. 
Nonetheless, the 10-year follow-up of the UKPDS study shows strong evidence that tight 
glycaemic control not only reduces microvascular complications but also macrovascular 
complications such as myocardial infarction and all-cause mortality [46]. The risk of severe 
cardiovascular complications is more than doubled in patients with T2DM compared to the 
general population [47, 48]. However, the incidence and risk of macrovascular morbidity and 
all-cause mortality has decreased substantially both in patients with diabetes and in the 
general population over the last two decades [49]. Research results collectively emphasise the 
importance of improved glycaemic control and progressive multifactorial risk reduction in 
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patients with T2DM to delay or prevent diabetes-related complications and premature death 
[50-53]. 
3.1.5 Diagnosis 
Diabetes is a complex variety of diseases but with chronic elevated plasma glucose levels in 
common. Accordingly, diabetes may be identified based on plasma glucose criteria; either by 
the fasting plasma glucose (FPG) value or by the oral glucose tolerance test (OGTT) [32].The 
diagnosis requires a fasting plasma glucose ≥7mmol/L or a 2-hour venous glucose over≥ 11.1 
mmol/L (after an oral glucose load of 75 g), alternatively a random venous plasma glucose ≥ 
11.1 mmol/L, if there are simultaneous symptoms of hyperglycaemia [33, 54].  
The diagnosis can also be made by measuring HbA1c. The HbA1c is a marker of the average 
blood glucose levels over the previous 4-6 weeks, [55]. This method does not require fasting 
and is more convenient compared with the FPG and OGTT. These benefits may be balanced 
by lower sensitivity, increased cost, limited availability of HbA1c testing in parts of the 
developing world, and the poor association between HbA1c and average glucose in some 
patients [54, 56].  
If the patient has symptoms of hyperglycaemia, the diagnosis of diabetes requires only one 
single randomised plasma glucose test. If no symptoms are present, two consecutive tests are 
required for diagnosis.  
 
Table 1. Presents diagnostic limit values for diabetes. 
 
Plasma Glucose HbA1c  
Venous Capillary 
 
Fasting Plasma Glucose  ≥ 7mmol/L ≥ 7mmol/L 
 
Oral Glucose Tolerance  ≥ 11.1mmol/L ≥ 12.2mmol/L 
 
Random Plasma Glucose   ≥ 11.1mmol/L ≥ 12.2mmol/L 
 
HbA1c  
  
 ≥48 mmol/mol  
Normally, FPG, OGTT and HbA1c could all be used to diagnose diabetes. However, one 
method only is not sufficient to identify the diagnosis of diabetes in every individual therefore 
the diagnostic methods do not replace each other but partly identify different groups with 
elevated plasma glucose. 
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3.1.6 Treatment 
Lifestyle intervention is the basis for treatment of type 2 diabetes, but pharmacological 
treatment of hyperglycaemia is needed in most patients sooner or later due to the progressive 
nature of the disease.  
Glucose-lowering drugs 
Today, there are a variety of drugs that lower blood glucose with different mechanisms of 
action. For optimal drug selection, the prescriber should consider factors that the individual 
can influence (attitude, treatment compliance and support from relatives) but also factors that 
the individual cannot influence (age, expected short life, other severe chronic disease and 
cardiovascular disease). In addition to this, other factors such as obesity, long diabetic 
duration, renal dysfunction, risk of hypoglycaemia and price are also crucial for drug 
selection to optimise treatment [51]. The number of GLD classes has increased over the past 
two decades. An overview of the most commonly used drugs for diabetes mellitus are given 
below. 
Biguanides (metformin) lowers blood glucose levels primarily by decreasing the amount of 
glucose produced by the liver. Metformin also helps to lower blood glucose levels by making 
muscle tissue more sensitive to insulin. Recent evidence suggests that metformin has some 
glucose-lowering action directly via the intestine, it does not lead to hypoglycaemia and is 
considered to be weight neutral [57]. 
Sulfonylurea (SU) stimulates the β-cells of the pancreas to release more insulin. There is 
concern that this class of drugs may overwork the pancreas, thereby speeding up the 
progression of type 2 diabetes. The risk of weight gain and hypoglycaemia is increased in 
patients treated with sulfonylurea [58].  
Glitazones lower the level of blood sugar and affect the fat cells to increase sensitivity to 
insulin. However, the maximum effect will come after 2-3 months. The drug is therefore 
rarely suitable for monotherapy if the purpose of the treatment is rapid HbA1c reduction. 
Pioglitazone should not be used in heart failure. The drug is associated with weight gain [59]. 
Alpha-glucosidase inhibitors inhibit carbohydrate uptake from the intestine to the blood. 
Since more carbohydrates remain in the gut, the incidence of gastrointestinal side-effects is 
high. This class does not produce hypoglycaemia. The high incidence of gastrointestinal side-
effects and the modest effect on HbA1c limit the use of the drug [58]. 
Incretin-based drugs 
After food intake, the hormone incretin is formed in the intestine which affects the pancreas. 
The hormone causes the pancreas to increase insulin production and provides a faster sense of 
satiety [60]. This stimulation occurs through a glucose-dependent mechanism, which causes 
the insulin release to stop if blood glucose drops below 5 mmol/l. Incretin treatment is 
divided into GLP-1 agonists (subcutaneous injection treatment) and DPP-4 (dipeptidyl 
peptidase-4) inhibitors [60]. 
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GLP-1 agonists: GLP-1 is a hormone produced in the small intestine that stimulates insulin 
secretion and inhibits glucagon secretion, thereby lowering blood sugar. Shorter-acting 
agonists of the GLP-1 receptor are particularly effective at lowering post-meal glucose peaks, 
whereas longer-acting GLP-1 agonists have more balanced effects on lowering post-meal and 
fasting glucose levels. GLP-1 agonists improve the glycaemic control without causing 
hypoglycaemia and may also result in weight loss [60].   
DPP-4 inhibitors: GLP-1 is inactivated in the blood by the enzyme dipeptidyl peptidase-4. 
When the glucose levels are elevated, the activity of the DPP4-inhibitor increases levels of 
GLP-1, which stimulates insulin production and decreases production of glucagon. DPP-4 
inhibitors improve the glycaemic control without causing hypoglycaemia and are generally 
weight-neutral, although modest weight loss has been observed [61].  
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are the most recently introduced 
group of GLD; the glucose-lowering effect is induced by increased glucose secretion in the 
urine. Glucose in the bloodstream passes through the kidneys, where the glucose can be 
excreted or reabsorbed. SGLT2 work in the kidney to reabsorb glucose, and the SGLT2 
inhibitors block this action and glucose will be eliminated with the urine. Because of the 
increased glucose levels in the urine, side-effects can include urinary tract and yeast 
infections [59, 62]. The effect of these drugs is independent of insulin resistance and beta cell 
failure, therefore a similar HbA1c-lowering effect is seen in the onset of type 2 diabetes as in 
long-term diabetes. Other beneficial effects of treatment with SGLT2 inhibitors may be a 
slight weight reduction. However, the glucose-lowering effect decreases with renal 
impairment (eGFR <45 ml/min) [51]. 
Oral combination therapy: Because the drugs listed above act in different ways to lower 
blood glucose levels, they may be used together. Combination therapy is designed to improve 
efficacy; switching from one single drug to another is not as effective as adding another type 
of glucose-lowering drug. 
Insulin is a hormone produced by the pancreas that stimulates cells in the body to remove 
glucose from the blood for storage or use. Normally, insulin is released when the body has 
high amounts of sugar in the blood, such as after a meal, to bring levels back into a normal 
range. Today there are a large number of different insulin regimens. Commonly a morning 
injection of long-acting or intermediate-acting insulin is given but administration at bedtime 
may also be necessary. There is also short-acting insulin usually administrated with meals 
[63]. Treatment with insulin in type 2 diabetes is superior if there is a need for rapid glucose 
lowering or in case of pronounced beta cell failure. Similarly, insulin can be used if there is 
contraindication to other GLD. Insulin treatment increases the risk for hypoglycaemia and 
risk for weight gain.  
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3.1.7 Treatment goals  
Glycaemic control minimises the risk of developing complications. Therefore reasonably 
priced, safe and efficient GLD are essential for the survival of individuals with diabetes. 
Guidelines propose intensive glucose-lowering treatment, preferably with metformin, at or 
just after diagnosis [53, 64, 65]. Sweden has national guidelines that recommend a target 
level of HbA1c of less than 53mmol/mol, which is similar to other international guidelines 
[53, 65, 66]. However, recently the Swedish Medical Products Agency recommended 
personalized treatment for individuals with long-term diabetes and with existing 
complications; the treatment goals could then be less intensive. However, HbA1c> 70 
mmol/mol increases the risk of complications and may lead to hyperglycaemic symptoms 
with impact on the patient's quality of life, and should always be avoided [51, 53]. Despite 
clear treatment guidelines, good access to healthcare and subsidized GLD, actual 
achievements of target levels of HbA1c in routine clinical practice are poor. In Sweden less 
than every second patient with T2DM achieves the recommended HbA1c target levels [67, 
68]. 
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3.2 INADEQUATE USE OF MEDICINE 
3.2.1 Terminology and definitions 
Regular adherence to GLD plays a fundamental role of glycaemic control in improving 
patients’ health outcomes. However, inadequate use of medication is identified as a frequent 
and age-old problem. The purpose of this section is to provide a short guide regarding the 
meaning and use of the terms as they relate to evolution of a long-standing problem, Figure 1.  
 
Figure 1. Simplified timeline of terminology for inadequate use of prescribed treatments 
and quotes adapted and modified from new taxonomy for adherence to medications 
[69]. 
 
There are a variety of terms to describe adherence to medicine and there is a lack of 
consistency in the terminology. However, compliance, adherence, persistence and 
concordance are the most widely used terms to describe the adequate use of medicine. The 
terms are all used when evaluating patients’ agreement to prescribed treatment plans, but the 
terms impose different views and have altered meaning [69-71]. Regardless of the exact term 
used to describe inadequate use of medicine, the consequences are destructive and with large 
variation. Some patients will present with therapeutic failure, and others may experience side-
effects, some experience disease progression and in the worst cases, premature death. 
However, this thesis will focus on the term “non-adherence” and the wider expression 
“inadequate use of medicine”, because the latter expression could describe both patients’ and 
providers’ erroneous behaviour, including intentional or unintentional inappropriate actions. 
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Compliance  
Compliance is the most common term for describing patients taking their medicine as 
recommended by their clinician. The expression; ”patient non-compliance”, was defined in 
“Compliance in health care” by Haynes et al., 1979 as a lack of coincidence between the 
patient’s behaviour, in terms of taking medications, following diets, or executing lifestyle 
changes, and clinical prescriptions [10]. Patient compliance has been a Medical Subject 
Heading (MeSH) term since 1975 [69]. When searching the MeSH term “patient compliance” 
in the PubMed database it resulted in more than 70,000 publications (Feb. 2019). In literature, 
compliance refers to a patient who passively follows the physician’s orders which indicates 
that the treatment plan is not a collaboration between the physician and the patient [72].  
Adherence  
Medication adherence was introduced as a MeSH term in 2009 and represents a more up-to-
date term, as it refers to an agreement regarding the treatment plan between the physician and 
the patient [8, 69]. Adherence is suggested to be separated from the term compliance because 
of the two-way communication [8, 71]. Today there are more than 15,000 publications with 
the MeSH term medication adherence. Most of the articles are published later than 2011, in 
the PubMed database. However, both adherence and compliance refer to the degree to which 
a patient actually takes the prescribed medicine with respect to timing, dosage and frequency, 
and many researchers consider the two terms synonymous [71]. Further, compliance and 
adherence to medicine could both be continuous and categorical variables which could be 
used to evaluate inadequate use of medicine, over a period of time [71, 73]. 
Concordance  
The term concordance is even more recent but not synonymous with either compliance or 
adherence. The term was introduced in 1997 and focuses on the healthcare provider and the 
patient consultation process rather than on a patient’s medicine-taking behaviour [70]. It is 
based on the concept that the consultations between clinicians and patients is a negotiation 
between equals [74]. The idea is that patients that actively participate in the decision-making 
will improve medication-taking behaviour [75]. Concordance focuses on the agreement 
process and does not estimate the patient’s behaviour in terms of taking medications. 
Persistence  
To evaluate how long a patient continues with the treatment, from initiation to 
discontinuation, compared to the recommended duration is called persistence [69, 71]. Non-
persistence is usually evaluated by refill gap algorithms and refers to the absence of dispensed 
medication within the adequate time period. Non-persistence relates to when a patient decides 
to stop taking a medicine; the term covers both discontinuers and patients with inadequate use 
[73]. There are many publications which include the word persistence, but the term is still not 
a MeSH term. The risk of developing complications is affected by adherence, particularly 
with regard to how long the patient has been taking the medication. However, a patient who 
is identified as persistent with the prescribed medicine is not always considered as an 
adherent patient (Figure 2) [70, 73]. Both adherence and the period of time patients take their 
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medication affect the medical outcomes, hence both adherence and persistence should be 
evaluated to characterise adherence comprehensively [71].  
 
Figure 2. The diagram is illustrating the overlap of non-adherence and non-persistence, 
adapted and modified from Parker MM et al., J Am Med Inform Assoc. 2015 [73]. Non-
adherence captures A and B but not C and non-persistence captures B and C. 
 
Prescription drug misuse  
“Prescription drug misuse” is a new MeSH term introduced in 2013 describing inadequate 
use of drugs or medications outside the intended purpose, scope, or guidelines for use. This 
term differs from medication adherence and is altered from drug abuse, which is more of an 
obstinate action. Further, prescription drug abuse is a major public health problem [76]. There 
are already more than 11,000 publications in the PubMed database with the MeSH term 
“prescription drug misuse”. 
Primary non-adherence  
Primary non-adherence is when the healthcare provider prescribes a medication, but the 
medication is never dispensed, meaning that the patient does not initiate treatment at all [77].  
Inappropriate prescribing 
“Inappropriate prescribing” is a MeSH term introduced in 2011, with more than 2,000 
publications in 2019, which describes the practice of administrating medications in a manner 
that poses more risk than benefit, particularly where safer alternatives exist. This term has 
similarities with the term “prescription drug misuse”, which is defined as improper use of 
drugs or medicine outside the purpose, scope or guidelines for use. 
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3.2.2 Measuring adherence   
Methods for assessing adherence to medicine   
Measurement of medication adherence can be challenging. There are numerous tools 
available to estimate adherence and a variety of direct and indirect methods to measure this 
behaviour. However, currently there is no single method to estimate adherence perfectly and 
a combination of methods is recommended [78-81]. Further, the diversity of methods and 
absence of a classification of adherence make the interpretation of adherence challenging and 
limit the ability to compare results from different studies. Approximations of adherence could 
also differ among diseases or among subgroups of patients, distinguished, for example, in 
terms of comorbidity, gender, educational level, age, or insurance coverage [82-84]. In this 
thesis patient-reported outcomes and refill adherence with focus on refill gaps are used to 
estimate inadequate use of medicine. Most methods for estimating adherence described in the 
literature are summarised in Table 2. 
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Table 2. Methods for assessing adherence to medicine [8, 72, 81, 85]. 
 
Method  Direct / 
Indirect  
Type of Data  Advantages  Disadvantages  
Drug level in 
biological fluids  
Direct  Qualitative  Objective 
Recent use verified  
Possible to compare with 
standardised relationship 
regarding drug 
concentration and effect 
Data limited to recent use 
Patient-specific kinetic variations  
Risk of white coat adherence  
Biological markers  Direct  Qualitative Objective  
Recent use verified 
Data limited to recent use  
Only yes/no response, no level of 
adherence 
Patient-specific kinetic, expensive 
Direct patient 
observations 
Direct  Quantitative  Objective  
Verified use  
Impractical in outpatient settings 
Patient Interview  Indirect  Qualitative Easy to use/inexpensive 
Information about 
circumstances 
Influenced by question construction 
and interviewer´s skill 
Patient diary  Indirect Qualitative Information about 
circumstances  
Influenced by construction 
Patient 
questionnaire  
Indirect Qualitative Easy to administer 
May explain patient 
behaviour  
Inexpensive  
Commonly used method 
may allow comparisons 
between studies  
Lack of continuous data accuracy is 
instrument-dependent  
May overestimate adherence  
Cognitive or memory limitations 
may impact assessment 
Pill count  Indirect Quantitative Objective  
Easy to use 
Inexpensive 
Lack of medication timing  
Overestimation of adherence due to 
“dumping pills” 
Pharmacy records  Indirect Quantitative Objective  
Non-invasive 
Long-term data 
Large population  
Requires comprehensive pharmacy 
records  
Dispensed medicine is not equal to 
ingestion of medicine  
Electronic 
monitoring 
 
Indirect Quantitative Continuous data  
Date and time-specific 
regarding drug intake   
Expensive  
Inconvenient  
The patient may open the drug 
container without taking the correct 
amount of the drug  
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Quantification of adherence to medication  
Adherence is not always perfect or totally imperfect; it can vary between individuals and may 
also vary in a given individual over time. However, adherence is often a dichotomized 
variable, adherent or non-adherent in quantitative evaluations, which is also the case in this 
thesis. The most common methods for quantifying adherence over a defined time interval are 
described below [69]:   
1. The proportion of drug taken or dispensed  
2. The proportion of days with the correct number of doses taken or dispensed 
3. The proportion of doses taken, in relation to a defined time interval between consecutive 
doses 
4. The distribution of dose intervals  
5. The number of (drug holidays) treatment gaps 
6. The longest interval between two doses 
Refill adherence  
Many researchers have used pharmacy records to estimate refill adherence, i.e. the total 
amount of dispensed medicine in relation to the number of days between refills [72, 86, 87]. 
There are several methods to evaluate medication refill adherence, estimate persistence with 
focus on the duration of drug refill, measure the amount of dispensed medicine in relation to 
time or assess refill gaps within a period of persistence [88-90]. 
The Medication Possession Ratio (MPR) method is based on the number (or percentage) of 
days with dispensed drug during a definite period of time or a period of refill intervals. 
Another widely used technique is gap measures, e.g. examination of medication gaps (CMG) 
that estimates if a patient refilled the medication according to the treatment period. These two 
methods are commonly used to classify patients with good or poor medication refill 
adherence using “cut-offs” to dichotomize patients [90, 91]. The assumption that could be 
questioned is that a patient either underuses or stops using the medicine if they do not refill 
medication as recommended. The most frequent “cut-offs” in the literature for non-adherence 
is MPR <80% and CMG >30 days [92]. Both MPR and CMG have been found to be 
appropriate statistics to recognise suboptimal medication refill adherence [29]. However, with 
a cut-off at 80%, patients are considered as adherent even when they miss one week of 
medicine during a month. Non-persistence and poor adherence are both associated with 
extended gaps between refills when using pharmaceutical claims. However, outcomes on 
refill adherence must be carefully extrapolated, since methods may vary between studies and 
the choice of method may influence the estimated refill adherence [86, 89, 92, 93]. The major 
limitation of refill adherence is the estimation of dispensed drugs and not if the patient is 
really taking the medicine [87]. This is obvious and a well-known dilemma, but dispensed 
prescriptions are a better surrogate for actual drug intake than a written prescription even if 
results may overestimate actual adherence. 
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In this thesis data from pharmacy records are linked with other data stored in population-
based registries to explore factors associated with estimated refill non-adherence which is 
mainly based on medication gaps of glucose-lowering drugs. 
3.2.3 Barriers for adherence  
Adherence to medication is a complex interaction between the social environment, the patient 
and the healthcare providers. The problem of poor adherence to medical regimens is 
commonly recognised and widely researched; however the underlying reasons or contributing 
factors are still not fully understood. Knowledge of barriers for adherence is a prerequisite for 
efficient improvement. Non-adherence includes both underuse and overuse even if underuse 
seems to be more common and therefore more researched. The most common problems 
associated with taking medicine as prescribed are incorrect doses or delays in the timing of 
doses [85, 94]. There is a vast heterogeneity in non-adherence which highlights the 
importance of a broader awareness of the reasons leading to non-adherence or inadequate use 
of medicine [77].  
The patient usually has a reason for missed doses or discontinuation of prescribed 
medications; many of the reasons are behavioural and non-adherence is therefore often 
dichotomized by the patients´ intent, as non-intentional or intentional [95, 96]. Nevertheless, 
most patients who are identified to be non-adherent seem to actively choose to neglect the 
treatment recommendations [96].  
Intentional non-adherence 
Most people think non-adherence is because of deprived memory or lack of access but it is 
often an intentional choice by the patient, Figure 3. Intentional non-adherence is associated 
with an individual’s beliefs and cognition. Anxiety of experienced side-effects could cause 
patients to decrease the dose or stop their refill of medication. A study which included 
patients from several European countries stated that individuals with T2DM who experienced 
symptomatic hypoglycaemia reported more obstacles to medication adherence than 
individuals with no experiences of hypoglycaemia [97]. 
Insufficient knowledge and negative attitude towards the treatment or an obvious conflict 
between the treatment recommendation and daily life are considered to be barriers for 
adherence [96]. Patients are more likely to become non-adherent for chronic diseases where 
the patient has no or less experiences of unpleasant symptoms [77]. Other barriers associated 
with intentional non-adherence are feeling well without treatment, lack of motivators or 
increased personal costs [8, 96, 98]. However, patients usually do not tell a physician (83%) 
that they are not going to refill the prescription. While the physician believes most patients 
(91%) adhere to the prescribed regimen, a consequence of the main problem is that non-
adherence frequently remains unseen [99]. 
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Non-intentional non-adherence 
Non-intentional non-adherence factors are associated with age and clinical variables such as 
depression, anxiety, and can occur when a patient intends to adhere but is prevented by 
forgetfulness or incapability, due to different underlying barriers [96], see Figure 3. 
 
Figure 3. Reasons for non-adherence*.  
*Adapted from analysis of a patient survey with 10,000 patients (2002), published in “The hidden epidemic: 
Finding a cure for unfilled prescriptions and missed doses”, Boston Consulting Group, December 2003, 
https://www.bcg.com/documents/file14265.pd (attached 2016-06-29) ** Wroe AL (Wroe 2002) 
 
Environmental barriers for adherence  
Patient-related barriers represent only a fragment of the variety of problems of non-adherence 
[8, 100]. Non-adherence is also influenced by complex drug regimens, comorbidity, adverse 
side-effects, personal costs, unclear agreements between patients and professionals, lack of 
symptomatology, access barriers, demographic factors and psychosocial issues such as lack 
of education and socioeconomic-related barriers [8, 72, 77]. Collectively, it has been shown 
that suboptimal adherence to GLD in individuals diagnosed with diabetes is related to 
socioeconomic and psychosocial factors [101-104]. Poor health literacy and the talents 
needed to function successfully in a healthcare environment have been recognised as a 
possible contributing factor in non-adherence [105, 106].  
There is a need for a holistic and better understanding of barriers to improve medication 
adherence [96, 98]. Furthermore, strategies that address more than one of the barriers 
simultaneously are recognised as more successful to improve medication adherence and 
which probably result in improved patient outcomes [98] [107].  
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3.2.4 Consequences of inadequate use of GLD  
Medication non-adherence has several negative consequences for patients, healthcare 
providers, pharmacies, pharmaceutical companies and society. The consequences of non-
adherence to medicine could lead to disease progression, complications, dysfunctional 
behaviours, poorer quality of life, inflated use of healthcare resources and premature death 
[77, 108, 109].  
Patients with T2DM who dispensed less than 80% of the prescribed GLD over one year were 
at a significant increased risk of hospitalisation [110]. Moreover, it is shown that high levels 
of adequate use of medication in individuals with diabetes mellitus were associated with 
lower disease-related medical costs [111].  
The estimated economic burden of inadequate use of medicine makes it a major medical 
problem globally. Healthcare providers would benefit from follow-up outcomes and consider 
the possibility of poor adherence to medicine as an explanation for therapy failure. In patients 
treated with GLD, poor glycaemic control indicates inadequate use of GLD, and occasional 
non-adherence to medicine which is recognised as one of the primary causes of 
hyperglycaemic events [68, 69]. 
It is crucial to study contributing factors related to non-adherence to facilitate the 
identification of non-adherent patients to be able to design effective interventions for the 
purpose of improving adherence. Patients, payers, healthcare providers, pharmacies and 
pharmaceutical companies stand to benefit if patients take their prescribed drugs as directed. 
Given the complexity in improving medication adherence, achieving mutual benefit most 
likely requires a collaborative effort from all the parties in the healthcare delivery chain.  
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3.3 POPULATIONBASED RECORDS  
General  
This thesis includes data from several established national health registries. Large-scale 
observational registries are well suited for descriptive studies to investigate associations 
between patient characteristics and risk of disease and mortality [112]. Sweden has a 
longstanding tradition of creating nationwide administrative, population-based or disease-
specific quality registries, which are a treasure for research. Since 1967, every Swedish 
citizen and inhabitant has a unique 12-digit personal identification number (PIN) recorded in 
all registries, which allows person-identification of significant quality and offers an exclusive 
opportunity to link information from several sources [113]. The data are usually complete and 
valid, and the coverage is good in the Nordic countries, therefore the limitations are often 
overlooked. However, the most prominent problems in registry-based research are data 
selection and data quality, including missing data for some variables [112]. The main 
strengths of registry-based studies are that data at the time of the study already exist. In 
addition, study populations are more or less complete; the risk of selection bias is low since 
data are independently collected. Registry-based studies facilitate research of large 
populations which enable evaluation of rare conditions and end-points. One of the central 
limitations includes the probability that important information may be missing or unavailable, 
data collection is not following a protocol and is not done by the researcher, confounder 
information is lacking and also information on data quality is missing. Limitations that are 
inherent to all observational studies must be considered. Because patients are not randomised, 
it is significantly more difficult to prove a cause-relationship between exposure (e.g. risk 
factor, treatment) and clinical outcomes of interest. 
 
The national patient registry (NPR) 
Information from all 21 county councils in Sweden has been distributed to the National Board 
of Health and Welfare (NBHW) since 1987 and comprises all in-patient care in Sweden 
[114]. Since 2001 the registry holds information on all Swedish citizens and residents 
containing hospital admissions as well as outpatient visits, including day surgery and 
psychiatric care from all healthcare providers. The coverage of the NPR is nearly 100% 
[114]. It should be noted that the positive predictive values of diagnoses assigned after 
hospital admissions due to “trauma and fractures” were found to be 95% or above when 
compared with medical records [114]. However, there is not yet a national registry covering 
visits in primary care or outpatient visits to personnel other than physicians (such as nurses, 
social workers or psychologists) in specialised healthcare facilities. For the individuals 
included in the studies presented in this thesis, information on discharge diagnosis, using 
ICD-10 (International classification of disease) and related health problems, has been 
retrieved [114].  
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The Swedish prescribed drug registry (SPDR)  
The Swedish prescribed drug register (SPDR) is held by the NBHW and contains individual-
level data on all dispensed prescription drugs by Swedish pharmacies since July 1, 2005 
(100% coverage) [115]. This nationwide registry includes data on dispensed prescriptions of 
pharmaceutical drugs that individuals have collected from a Swedish pharmacy with the 
potential of individual‐level linkage to other registers. It includes data on prescribed 
medication, ATC-code, dosage, amounts, and defined daily dose. However, it does not 
include drugs that are delivered during hospital visits. It is one of the biggest population-
based pharma-epidemiological databases in the world and offers high quality data for 
research [115]. A limitation could be, however, that the SPDR does not include data on over-
the-counter drugs. 
The Swedish national diabetes registry (NDR) 
The Swedish National Diabetes Register (NDR) includes more than 500,000 individuals with 
diabetes and was initiated by The Swedish Society for Dialectology. The NDR includes more 
than 92% of individuals who are 18 years of age and diagnosed with diabetes mellitus in 
Sweden [116]. The registry stores disease-related variables describing patient characteristics.  
The longitudinal integration database for health insurance and labour market studies 
database (LISA)  
The longitudinal integration database for health insurance and labour market studies database 
(LISA) [117] managed by Statistics Sweden provides information about socioeconomic 
status such as education, income, number of people living in a household and marital status. 
Since 1990, the database has included complete information on all individuals from 16 years 
of age. The individual is the main objective, but associations to family, companies and places 
of employment are also accessible.  
National forensic medicine database (NFMD) 
The National Forensic Medicine Database (NFMD) is held by the Swedish National Board of 
Forensic Medicine and represents a real-time database that is continuously built up of data 
from the routine casework at this agency. This case management system, originally named 
RattsBase, was introduced 1991 and in parallel, a similar system was developed for the 
Swedish national forensic toxicology laboratory. Both systems were developed with the 
intention to facilitate the routine casework, but also to make it possible to create databases 
that could cross-talk, in order to allow for evaluation of postmortem toxicological results. The 
data in NFMD are very reliable since they have been used to generate information on referral 
notes, labels, autopsy reports that are sent to the police, and death certificates. If errors are 
noticed in-house or by recipient, the correction will not be in the particular document but in 
the system, and this correction will automatically appear in NFMD [118].   
In Sweden all obvious or suspected unnatural deaths, as well as obscure deaths, should be 
reported to the police. The police will then almost always decide to request a forensic 
autopsy. Registered data from postmortem examinations contain detailed information about 
each subject, including age, sex, cause(s) of death, incidental evidence, and medical history. 
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In addition, autopsy findings contain outcomes of numerous additional examinations, e.g. 
microscopy and forensic toxicology, including routinely collected femoral blood, urine and 
vitreous humour [119].  
The Swedish cause of death registry (CDR) 
The cause of death registry, now held by The National Swedish Board of Health and Welfare, 
has been recording mortality with complete information (99.1%) since 1952 [120]. The 
registry includes data on age, sex, date of death and ICD-10 codes regarding underlying and 
contributing causes of death [120]. The registry covers mortality data for all individuals who 
at the time of death were Swedish citizens, regardless of whether the death occurred within or 
outside the country. In addition, from 2012 it also covers deaths that occurred in Sweden even 
if the individuals were not Swedish citizens at the time of death [120]. 
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4 STUDIES IN THIS THESIS  
Table 3. Studies in this thesis.  
 Study I Study II Study III 
Status  Published  Published  Submitted  
Design  Multicentre study, 
observational  
Case control study, 
observational   
Cohort study, 
observational 
Outcomes  Hypoglycaemia  
Treatment satisfaction 
Adherence 
Glycaemic control 
Fatal hyperglycaemia 
Associated risk factors  
Glycaemic control  
Concentration of 
metformin post-mortem 
Fatal intoxication 
Ass. risk factors  
Glycaemic control 
 Cross-sectional  Retrospective  Retrospective 
Study sample 430 patients in primary care 
with type 2 diabetes  
 
322 forensic cases with 
hyperglycaemia + living 
controls  
122 forensic individuals 
All with metformin in 
femoral blood  
Measure  adherence  Indirect measure  
Patient-reported adherence  
Dichotomized adherence 
Indirect measure 
Refill adherence; with or 
without refill gaps  
Indirect measure  
Refill adherence;  
Daily doses dispensed   
Data source Self-reported questionnaires 
Medical records 
Police reports + NFMD a 
Linked registry data  
NDR b, SPDR c, LISA d, 
NPR e  
Police reports + NFMD 
Linked registry data  
NDR, SPDR, NDR NPR 
GLD f Metformin/SU  All GLD  Metformin  
 
Type of inadequate 
use of GLD 
Non-adherence,  
underuse  
Non-adherence, underuse, 
inadequate use   
Non-adherence, overuse,  
inadequate use,   
inappropriate prescription 
 
Statistics  
Tests; Student´s t, Kruskal-
Wallis, Mann-Whitney U, χ2  
Cochran Mantel –Haenszel 
 
Analysis of covariance 
Test of independence 
Tests; Student´s t, χ2 
Mann-Whitney U test  
Odds ratio 
Univariate logistic 
regression  
Multiple logistic regression 
Tests; Student´s t, χ2 
Mann-Whitney U test  Kruskal-Wallis 
Consequences of 
inadequate use of 
GLD 
Adverse events, hypoglycaemia  
Glycaemic control  
 
Death due to 
hyperglycaemia  
Glycaemic control 
Death due to metformin 
intoxication  
Glycaemic control   
 
Studied risk factors  
Symptomatic hypoglycaemia  
Treatment satisfaction  
Barriers for adherence  
 
Comorbidity 
Diabetes-related variables  
Socioeconomic status  
Psychosocial status 
Pathology  
Comorbidity 
Diabetes-related variables 
Psychosocial status 
Pathology  
 
a) National forensic medicine database 
b) The Swedish national diabetes registry 
c) The Swedish prescribed drug registry 
d) The longitudinal integration database for health insurance and labour market 
studies database 
e) The national patient registry 
f) Glucose lowering drugs 
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5 AIMS 
General Aim  
The overall aim of this thesis is to examine consequences derived from inadequate use of 
GLD in individuals with diabetes mellitus in Sweden as well as to further explore risk factors 
for serious consequences of inadequate use of GLD.  
 
Specific Objectives: 
 
I. To study the impact of symptomatic hypoglycaemia on medication adherence, 
and on patient satisfaction with treatment, in relation to glycaemic control in 
patients with T2DM treated with a combination of metformin and sulfonylurea.  
 
II. To identify potential risk factors associated with confirmed fatal hyperglycaemia 
in individuals on glucose-lowering drugs. 
 
III. To determine fatal and non-fatal postmortem femoral blood reference 
concentrations of metformin, and to explore possible risk factors for fatal 
metformin intoxication.  
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6 STUDY POPULATIONS 
General: The overall aim of this thesis is to examine inadequate use of GLD in individuals 
with diabetes mellitus in Sweden. Accordingly, we have studied three different Swedish 
populations with assumed diabetes, with observable consequences that might indicate 
inadequate use of GLD. 
Study I: At 54 primary care accounts, 430 consecutive patients with T2DM, 35 years of age 
or older, treated with metformin and SU dual therapy were recruited by Swedish investigators 
between January 2009 and August 2009. Patients were enrolled during a regular visit at their 
general practitioner from all 21 county councils in Sweden. The centres represent a 
homogeneous cross-section of the Swedish diabetes population since the centres were of 
diverse sizes and located in different demographic areas, both rural and urban. 
 
 
 
Figure 4. Selection of study population in Study I. 
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Study II: Once the study cohort had been defined, in the NFMD comprising 322 individuals 
who died due to confirmed hyperglycaemia in Sweden from August 2006 to December 2012, 
registry data from four additional sources were obtained via linkage to the personal 
identification numbers of included patients. Deceased subjects (268) with recognised 
dispensed GLD were matched on age and sex, with living controls randomly selected in the 
SPDR. Each control was given an index date equal to the date of death of the matched case.  
 
 
Figure 5 Selection of cases and controls included in the study population in Study II. 
a) Identified in the national forensic medicine database (NFMD) in Sweden August 2006 to December 2012 
b) Death due to hyperglycaemic coma confirmed by two independent forensic pathologists 
c) Data retrieved from the Swedish prescribed drug registry (SPDR) 
 
Study III: This study population comprises all individuals with metformin in postmortem 
femoral blood, from September 2011 to December 2016 in Sweden. It was a retrospective 
registry-based cohort study, conducted on a nationwide group of 122 deaths where metformin 
was identified in forensic autopsies and registered in the NFMD. All included patients had 
dispensed metformin at a Swedish pharmacy the year before death and every patient with a 
recorded diabetes diagnosis in the NDR or NPR were diagnosed with T2DM. 
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7 METHODS 
In this thesis, a variety of indirect methods has been used to evaluate inadequate use of 
medication, since there is no gold standard to determine inadequate use [78-81]. Further, a 
diversity of consequences related to inadequate use of GLD have been scrutinised as well as 
pre-defined associated risk factors in the included papers in this thesis. 
7.1 SELF-REPORTED QUESTIONAIRS 
In Study I, a number of self-reported questionnaires were used to evaluate experiences of 
symptomatic hypoglycaemia, treatment satisfaction and adherence to medicine.  
Hypoglycaemia 
The Worry subscale of HFS-II estimated worry and anxiety around hypoglycaemic 
experiences, with a subscale of 18 items, and a 5-point Likert scale ranging from 0 (never) to 
5 (very often) were used [121-123]. Moreover, scores were compiled from a validated 
questionnaire covering 10 items on the frequency and seriousness stratified patients by 
severity of symptoms (none, mild, moderate, severe or very severe), consequently with earlier 
study dichotomized into no or mild symptoms and moderate or worse symptoms [122]. In 
line with a published review, the patients’ experiences of the interruption of ongoing 
activities in everyday life, due to the severity of symptoms of hypoglycaemia, was the 
platform for stratification [124]. 
Treatment Satisfaction Questionnaire for Medication  
The TSQM (version 1.4), a validated questionnaire, estimated patient satisfaction with 
treatment which covered four elements: Side-effects (four items), Effectiveness (three items), 
Convenience (three items) and Global satisfaction (three items). A score per element was 
considered ranging from 0 to 100, a higher score indicating superior satisfaction with 
treatment. 
Self-reported adherence and barriers  
Self-report is the most common method for assessing adherence in research and clinical care. 
Patients reported adherence to treatment in a questionnaire covering 13 items where response 
was indicated by yes/no or by using a 5-point Likert scale (five items) or an 8-point Likert 
scale (three items). Because of the potential risk of overestimating adherence, it is 
recommended to stratify adherence as a dichotomous variable when using self-report [125, 
126]. Therefore every patient who reported any failures following agreed treatment 
instructions regarding the GLD were categorised as non-adherent, which is in line with other 
studies that have used the same survey [97, 127, 128].  
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7.2 FORENSIC MEDICINE AND TOXICOLOGY DATA  
Forensic toxicology provides the basis for Study II and III in the present thesis, and therefore 
warrants some attention. Toxicological detection of pharmacological substances is central to 
modern forensic investigation, since a substantial proportion of the people in the western 
world regularly uses pharmaceutical drugs, and since the analysis for drugs is critical for the 
diagnosis of fatal intoxications and/or for the assessment of degree of influence of drugs in 
other forms of unnatural deaths. Femoral blood, urine and vitreous fluid, when available, are 
consistently collected at almost every forensic autopsy in Sweden. In most cases, alcohols 
and certain other small volatiles, such as acetone are analysed with head-space gas 
chromatography. Since September 2011, the femoral blood samples are subjected to a liquid 
chromatography (LC-MS-TOF) screening that covers almost all regularly encountered drugs 
on the market as well as most illegal drugs [129]. Before that a gas chromatographic 
screening with nitrogen-phosphorous detector (GC-NP) was used for screening of drugs 
[130]. Positive findings are confirmed with a variety of quantitative LC-MS or GC-MS 
methods. Certain drugs with complex chemical structures and properties, e.g. anabolic 
androgenic steroids, may not be captured by the screening, and will be analysed with special 
methods upon request. All the analyses are performed at one central laboratory, the National 
forensic toxicology laboratory at the Swedish National Board of Forensic Medicine. This 
laboratory has since several decades participated in analytical exchange programs and 
performed well compared to other forensic toxicology laboratories. The responsible forensic 
pathologist will interpret the results, often after discussion with the toxicologists. Reference 
information on postmortem blood drug levels are extensively used, in particular the reference 
data that has been generated from the NFMD data according to a strategy previously 
described [130].  
In Study II and III nationwide cohorts of deceased were selected from all the forensic 
medicine departments in Sweden. In Sweden, all obvious or suspected unnatural, unexpected 
or obscure deaths should be reported to the police. The police will then request a forensic 
autopsy in most of these cases. Information from the police and other sources, the forensic 
pathology and the forensic toxicology results are registered in a case management system, 
and a similar system is used at the national forensic toxicology laboratory [118]. These 
systems represent real-time databases, combined into the National Forensic Medicine 
Database (NFM D), hence extensive and detailed data are available for all fatal intoxications 
examined [118]. 
The study populations in Study II and III were identified by a search profile that takes 
advantage of a very precise cause of death registration. The PIN of the subjects together with 
a selection of variables containing relevant information for each study was submitted to the 
NBHW. Before that, the relevant information from the autopsy reports, police reports and 
medical records, when available, was transformed into computable variable in the file 
submitted. The NBHW then linked these data with selected information from population 
based registries and replaced the PIN with a serial number to ensure anonymity. Hence the 
final file from the NBHW contained both the forensic medicine and toxicology information, 
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and the information from the national registries held by NBHW, including comprehensive 
information about the history of comorbidity, dispensed pharmaceuticals, and 
socioeconomics and diabetes health-related variables from linked registries. The nationwide 
cohorts in this thesis have an advantage over most other similar epidemiological studies since 
the characteristics of the study populations and circumstances surrounding death are very 
well documented. 
Confirmed death due to hyperglycaemia  
Diabetes mellitus has become a major cause of death and hyperglycaemic episodes occur 
frequently in acute illness in individuals with or without diabetes. In Study II the focus was 
on acute hyperglycaemic episodes that could have caused or contributed to death rather than 
identifying patients with the disease. Independent forensic pathologists scrutinised autopsy 
results, police reports and other relevant information with the aim of finding confirmed 
deaths due to hyperglycaemia. In clinical practice, the most important biochemical markers to 
identify disorders in glucose metabolism are blood glucose concentration and glycated 
haemoglobin levels. However, postmortem it is difficult to identify disorders in glucose 
metabolism as a cause of death due to major changes in body fluids and other tissues [122, 
123]. The HbA1c is stable for several weeks after death, but short episodes of 
hyperglycaemia do not affect HbA1c, and hence HbA1c cannot be used to disclose an acute 
fatal hyperglycaemia [123, 124]. Further, the blood glucose concentration is not reliable 
postmortem since the blood glucose concentrations rapidly decrease to zero after death due to 
the extensive consumption by the surviving blood cells [131]. 
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However, vitreous humour is better preserved than blood after death, and a suitable matrix for 
analysis of glucose and other endogenous compounds. The vitreous body is a colourless, 
transparent gel that fills up the eyeball, and is devoid of cells. The eyeball has an isolated 
position, which makes it protected from postmortem changes and less affected by 
contamination and degeneration after death [132]. After an initial decrease in vitreous glucose 
levels during the first 24 hours, the glucose concentration in the vitreous stays stable [133]. 
Further, Zilg et al. reported that glucose levels >10 mmol/l in vitreous fluid strongly indicates 
fatal hyperglycaemia [133]. Accordingly, the primary inclusion criterion for fatal 
hyperglycaemia in Study II was a vitreous glucose level of > 10 mmol/L and where other 
causes of death could be ruled out. As a matter of fact, vitreous glucose values of 10 mmol/L 
are equivalent to about 26 mmol/L in blood [134]. Accordingly, patients in Study II most 
likely had glucose levels of at least 26 mmol/L (and in the majority of cases much higher 
levels) in blood before their demise [133]. 
 
Deaths with detection of metformin 
Screening for drugs has been routinely used at forensic toxicology laboratories for decades. 
In 2011, a new liquid chromatography/time-of-flight mass spectrometry (LC-MS-TOF) 
screening for drugs was introduced at the Swedish national toxicological laboratory [129]. 
This method can detect metformin, but like all other substances no quantitative results can be 
provided. Instead there is a LC/MS/MS verification method for metformin that can be used, 
either if the peak area of metformin is very large, or if the responsible forensic pathologist 
specifically requests an analysis of metformin.  
The initial population consisted of individuals where metformin was detected in femoral 
blood postmortem and logged in the NFMD. Two independent reviewers evaluated autopsy 
results, police reports and, when available, medical charts to stratify the cases as postmortem 
control cases or intoxication cases. A case was only included in the study if consensus 
between the two reviewers had been reached. However, forensic toxicology can only provide 
an estimate of substances present in a body at the time of sampling; hence, information of 
substances taken or exact doses of the consumed substances can often not be obtained [135].  
The control group in Study II, henceforth group C, consisted of postmortem cases where 
metformin was detected but the cause of death clearly excluded the incapacitation by this 
drug or other substances. Intoxication was ruled out in C cases since they were capable of an 
active action, according to a previously described procedure [130]. First, a rough selection 
was made based on the primary cause of death diagnosis by the forensic pathologist, and then 
all cases were subjected to a manual assessment by two independent reviewers. A case was 
only classified as a control case when consensus between the two reviewers had been 
reached. This strict inclusion and exclusion criteria as well as a manual multi-reviewer, case-
by-case evaluation for determination of fatal and non-fatal concentrations of pharmaceutical 
drugs has been applied for more than two decades [130, 136-138]. The postmortem control 
 32 
group (C) is mainly comprised of violent suicides and selected accidental trauma deaths, 
where incapacitation by drugs can be ruled out.  
Refill adherence  
In Study II and III pharmacy records are used for assessing refill adherence with the purpose 
of reflecting the continuity of medication use and capturing the timeliness and frequency of 
refill. Refill gap measures were used to identify patients who show inadequate medication 
refill adherence using “cut-offs” to dichotomize patients as being adherent or non-adherent 
[90, 91]. Many studies of medication non-adherence and non-persistence have used refill 
gaps algorithms, but the predefined allowable gap varies from 7-180 days. However, the most 
frequent cut-off in the literature to detect non-adherences is a predefined gap of 30 days or 
more [92]. In Sweden, one drug prescription typically corresponds to a maximum of three 
months’ continuous treatment, based on the structure of the Swedish reimbursement system 
[67, 86]. Therefore, patients with a minimum gap of 125 days between two dispenses of GLD 
were classified as inadequate refill adherence to medication [67, 139]. This method may be 
used regardless of product and dosage of the regimen. Hence, individuals with no evidence of 
dispensed GLD drugs 125 days or more before death/index date were considered as non-
adherent/non-persistent. 
Matched case-control design 
In Study II, a matched case-control design was used. Matched studies are common in the 
scientific literature, and their benefits and shortcomings have been extensively discussed 
[140]. It has been suggested that the main advantage of a matched case-control study is its 
ability to adjust for confounding [141], as well as a better effectiveness compared to an 
unmatched study [142]. However, by matching on a variable assumed to be a confounder, 
there is the possibility that a selection bias has been introduced, since the exposure among 
controls does not represent the exposure in the source population [141, 142]. Regarding study 
II, we matched deceased with living subjects treated with GLD regarding age and gender in 
our effort to control for confounders, but we cannot eliminate that we may have introduced a 
selection bias.  
Possible risk factors  
Several recent systematic reviews highlight a variety of factors that may be associated with 
non-adherence in patients treated with GLD, but further research is warranted to identify 
modifiable factors, since knowledge of risk factors is critical for improvement of adherence 
[13, 143, 144]. In this thesis, we studied selected factors that we considered relevant in 
clinical practice and which could be associated with inadequate use of GLD.  
In Study I, experiences of hypoglycaemia and treatment satisfaction were evaluated. Methods 
are described earlier in this thesis (self-reported questionnaires). 
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In Study II and III, comorbidity as well as disease-related factors were scrutinised as potential 
significant real-world risk factors. Relevant information was retrieved from the NDR and 
NPR; ICD-10 codes in the NPR were used to identify potential risk factors before the date of 
death/index. Examples of examined factors: history of macrovascular events, microvascular 
complications, last recorded HbA1c value, BMI, fatty liver disease, and history of psychiatric 
illness, including depression. Further, substance abuse was studied in both Study II and III. 
Individuals were categorised with substance abuse problems if they had a recorded discharge 
diagnoses of ICD-10 codes F10-19 (representing substance abuse, plus possible substance of 
abuse intoxication) [145] and/or if there was evidence of hospitalisation or outpatient hospital 
consultation at a clinic for substance abuse, retrieved from the NPR. In addition, we used 
police reports to identify well-known substance abuse.  
In Study II we also examined information about socioeconomic factors, including education 
level, income level, number of inhabitants in a household, employment status and marital 
status, collected from the LISA registry. In Study III we had no data from the LISA and 
therefore used information from the police reports to identify individuals living in a single 
household. 
7.3 STATISTICS 
Data were analysed using different versions of Microsoft® Office Excel 2010 software and 
SPSS v. 25, for Windows (SPSS Inc., Chicago, IL, USA). All tests were two-tailed and 
conducted at a significant level of p < 0.05.  
Descriptive statistics and hypothesis testing:  
Characteristics of individuals are presented as mean (± SD) with 95% CI for normally 
distributed variables (tested with Kolmogorov-Smirnov test); otherwise median and 
percentiles (25th-75th perc) are presented. Categorical variables are presented as number and 
proportions (%). 
Dissimilarities between groups are estimated using Student´s t-test or Mann Whitney U test 
for continuous variables and Chi-square tests for categorical variables, as appropriate. 
Further, the Kruskal-Wallis test was used when more than two groups were compared as in 
Study III when the medians of metformin were evaluated. All group comparisons in Study I 
were adjusted for differences in age, and p-values were assessed by means of analysis of 
covariance for continuous data and the Cochran Mantel-Haenszel test for categorical data. In 
Study I, the dependence between adherence and experiences of hypoglycaemia was tested. 
The test of independence was used to study the association between variables in cross tables; 
the null hypothesis was classified as the independent, meaning that Pearson Chi-squared P-
values <0.05 indicated a dependence between variables. 
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Logistic regression 
In Study II logistic regression analysis was used to obtain the odds ratio for predefined 
explanatory variables for fatal hyperglycaemia (the dependent variable). To categorise 
variables associated with confirmed fatal hyperglycaemia, variables probably associated with 
death due to hyperglycaemia were dichotomized and the odds ratios were at a first step 
calculated using univariate logistic regression models. Variables showing an association with 
fatal hyperglycaemia (p<0.05) were included into multiple logistic regression analyses using 
a stepwise elimination backward technique, where the least significant variable was removed 
for each step. We used the stepwise elimination backward technique to improve the 
prediction power with a minimum number of variables. The results were expressed as odds 
ratios (OR) with 95% confidence interval (CI). 
8 RESULTS 
8.1 GENERAL  
This thesis demonstrates several serious consequences that may derive from inadequate use 
of GLD, including that 20% of the patients treated with metformin and SU experienced 
serious hypoglycaemia, more than 300 individuals treated with GLD died outside hospitals 
due to confirmed hyperglycaemia during the study period in Study II. In addition 17 
individuals died during 2011-2016 due to unintentional metformin intoxication in Sweden.  
Inadequate use of GLD is an ongoing important problem with multifaceted expression, 
including refill gaps of GLD, self-reported non-adherence and inappropriate prescribed GLD. 
This thesis also reveals several risk factors associated with inadequate use of GLD.  
Noteworthy, a significant number of individuals identified with fatal hyperglycaemia were 
most likely undiagnosed, fatal hyperglycaemia was the first manifestation of diabetes 
mellitus. 
Finally, the results from all studies collectively showed an overall poor achievement of 
HbA1c target based on the treatment goals stated in the Swedish national guidelines.  
8.2 RESULTS FROM SPECIFIC STUDIES   
8.2.1 Study I 
In this study we found that almost one in three patients treated with metformin and SU 
experience any form of hypoglycaemia. More importantly, one in five patients experienced 
hypoglycaemic episodes of such severity that their daily activities were interrupted. 
The main finding is that adherence is negatively associated with the severity of the 
experienced hypoglycaemic symptoms (Figure 6A). 
Patients with moderate or worse symptoms of hypoglycaemia reported poorer adherence to 
medication (46% versus 67%, p<0.001) than patients with no or mild symptoms (Table 4).  
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The patients with moderate or worse symptoms of hypoglycaemia had significantly lower 
mean HbA1c values than patients with no or mild symptoms (7.0% versus 7.3%, p< 0.05) 
even though a greater proportion of patients with no or mild symptoms reported that they 
were adherent to GLD. 
Further, this study verifies that only 40% of the patients treated with metformin and SU in a 
primary care setting achieved the HbA1c target based on the treatment goals stated in the 
Swedish national guidelines. 
Table 4. Patient characteristics and study groups of no/mild symptoms versus moderate 
/worse symptoms of hypoglycaemia and groups of adherent versus non-adherent 
patients. Data expressed as the mean standard deviation for continuous variables and as 
a percentage for categorical variables.  
 
† 7.0% DCCT-standard (52 mmol/mol), ¤ HbA1c goal according to Swedish national guidelines. Missing 
patients are excluded, p-values age adjusted, *p<0.05 
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.  
 
 
Figure 6. (A) Proportion of patients who reported adherence with glucose lowering 
drugs in relation to severity of symptoms of hypoglycaemia. (B) Proportion of patients 
with HbA1c goal achievement based on the national guidelines in relation to severity of 
hypoglycaemic symptoms. 
Test of independence, Pearson´s chi-squared test, p<0.005. Missing patients were excluded. 
Patient reported outcomes measures (PROM) indicated that a number of predefined barriers 
to adherence were more frequent in patients with moderate or worse hypoglycaemia 
compared to patients with no or mild symptoms, shown in Figure 3. 
 
 
Figure 7. The overall scores of reported adherence and barriers to adherence (%) in the 
no/mild symptoms and moderate/worse symptoms of hypoglycaemia study groups age 
adjusted p-values. 
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Patients with no or mild symptoms of hypoglycaemia were more satisfied with the actual 
glucose-lowering treatment than the patients with moderate or worse symptoms (Table 5). 
Table 5. Treatment Satisfaction Questionnaire for Medication (TSQM) scores for all 
patients as well as the categories no/mild and moderate/worse hypoglycaemia. Data 
expressed as means and standard deviation (SD). 
 All patients 
(n=430) 
No/Mild 
(n=332) 
Moderate/Worse 
(n=80) 
p-
value 
TSQM dimension: Effectiveness (0-100) 69.7 ± 10.9 70.3 ± 10.8 67.7 ± 11.2 0.029* 
TSQM dimension: Side effects (0-100) 92.9 ± 16.2 94.4 ± 14.0 87.1 ± 21.8 0.0001* 
TSQM dimension: Convenience (0-100) 75.1 ± 12.0 75.6 ± 12.1 73.9 ± 11.6 0.081 
TSQM dimension: Global satisfaction (0-100) 70.3 ± 16.1 71.2 ± 16.2 67.0 ± 16.0 0.036* 
 
Notes: P-values are age adjusted missing patients are excluded data are expressed as the mean and standard 
deviation *p<0.05.Abbriviations: TSQM, treatment Satisfaction Questionnaire for Medication 
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8.2.2 Study II 
In this study the 322 included deceased individuals with fatal hyperglycaemia had a mean 
concentration of vitreous glucose of 39.5 ±19.4 mmol/L, which indicates very high blood 
glucose levels (≥75 mmol/L) antemortem [133]. 
The majority of the deceased with confirmed fatal hyperglycaemia were males (79%); most 
of them (71%) were between 45 and 75 years of age and treated with GLD (83%) and the 
majority had a history of insulin treatment. The police reports indicated that most of the cases 
who died due to fatal hyperglycaemia were dying alone (76%) and almost half of the cases 
(47%) had no diabetic medicine at the scene. Further, the overall glycaemic control was very 
poor. In diseased subjects 47% had an HbA1c ≥75 mmol/mol at the last healthcare visit. A 
significant number of the deceased (n=48, 15%) in this study had no dispensed GLD and no 
identifiable records of diabetes in the NPR. 
 
Risk factors associated with fatal hyperglycaemia  
This study evaluated several predefined risk factors that may have contributed to fatal 
hyperglycaemia. In summary, we found that several risk factors were significantly associated 
with increased risk of fatal hyperglycaemia. Table 6 shows odds ratios and CIs for all the risk 
factors associated with fatal hyperglycaemia. 
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Table 6. Results of the multiple logistic regression analyses, odds ratios and 95% 
confidence intervals for risk factors of fatal hyperglycaemia in individuals treated with 
GLD.   
Variables (yes/no) no = reference  
n= 265 cases/controls with diabetes  
 OR 95%  CI p 
Type 1 diabetes a 1.93 1.13-3.30 0.017 
Insulin treatment 4.40 1.96-9.85 <0.001 
No refill of GLD before death b 3.87 1.99-7.53 <0.001 
HbA1c ≥ 75 mmol/mol 2.00 1.23-3.27 0.005 
Microvascular disease 3.26 1.84-5.79 <0.001 
Psychiatric illness  2.30 1.32-4.01 0.003 
Mental disease due to substance abuse  23.8 4.57-123.6 <0.001 
Substance abuse  8.85 2.34-35.1 0.002 
Current smoker 1.81 1.06-3.09 0.029 
Single household 2.25 1.21-4.18 0.010 
Married c 0.39 0.17-0.87 0.022 
 
Variables that showed significance (p<0.05) in the univariate analysis were included in the multivariate analysis.  
Backward stepwise conditional logistic regression model was applied in 7 steps in all subjects.  
a. Diagnosed with type 1 diabetes, type 2 as reference  
b. Patients with no dispensed GLD drugs 125 days or more before death/index 
c. Married or registered partnership versus reference: unmarried, divorced, widow or widower 
 
8.2.3 Study III  
Between September 2011 and December 2016, 120 patients with metformin detected and 
quantified in postmortem femoral blood were included in the study. The majority of the 
population were middle-aged men. The metformin intoxication was considered to be 
intentional only in five (23%) of the single drug intoxications (A) and in three (23%) of the 
multiple drug intoxications (B). The intoxications had significantly higher median 
concentrations of metformin in femoral blood versus controls but had not dispensed higher 
mean doses/day of metformin than controls. In this study the glycaemic control is poor with 
only 37% reaching the HbA1c target. Participants’ characteristics for cases and controls are 
presented in Table 7A and 7B. 
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Table 7A. Characteristics of all individuals with confirmed metformin in femoral blood 
based on autopsy results, police reports and population-based registries. All subjects 
were stratified as single substance intoxication (A), multiple intoxication (B), 
postmortem controls (C) and cases with another cause of death (O). Number of 
individuals (%), mean (± SD) or median (25th-75th perc). 
 
a) Registered in the NDR 
b) Diagnosed with T2DM versus no confirmed diabetes diagnosis 
c) With dispensed drug from pharmacies during the same period as dispensed metformin 
d) With any contraindications to the use of metformin according to the SPC 
e) With dispensed drugs with risk of interactions with metformin according to SPC 
f) At last healthcare visit, registered in the NDR 
g) Estimated mean dispensed dose of metformin from pharmacies (g/day) last 90 days 
h) Estimated mean dose metformin higher than recommended daily dose in SPC, adjusted 
for kidney function 
  
Variables                                                    A                              B                                  C                                O 
Number of cases 22 (100%) 7 (100%) 13 (100%) 78 (100%) 
Metformin median (µg/g) 48.5 (30.5-98.0) 21.0 (8.20-26.0) 2.3 (1.25–5.35) 4.6 (1.78–8.78) 
Metformin (µg/g)min-max  13.0–210 4.40–95.0 0.70-21.0 0.64-54.0 
Gender (male) 14 (63.6%) 5 (71.4%) 10 (76.9%) 58 (74.4%) 
In the NDR a  20 (90.9%) 5 (71.4%) 12 (92.3%) 70 (89.7%) 
Type 2 diabetes b   21 (95.4%) 6 (85.7%) 13 (100%) 71 (91.0%) 
Insulin c 12 (54.5%) 2 (28.6%) 5 (30.8%) 29 (37.2%) 
Sulphonylureas c  8 (36.4%) 2 (28.6%) 7 (53.8%) 24 (30.8%) 
Living alone  19 (86.4%) 7 (100%) 9 (69.2%) 56 (71.8%) 
Suicide 5 (22.7%) 3 (42.8%) 4 (30.8%) 4 (5.1%) 
Known alcohol abuse  17 (77.3%) 5 (71.4%) 5 (38.5%) 32 (41.0%) 
Ongoing infection 6 (27.7%) 0 (0%) 0 (0%) 15 (19.2%) 
Dehydration 6 (31.6%) 1 (14.3%) 0 (0%) 15 (19.2%) 
History of CKD  9 (40.9%) 2 (28.6%) 3 (23.1%) 18 (23.1%) 
History of heart failure  1 (4.5%) 0 0 7 (9.0%) 
History of stroke 4 (18.2%)  1 (14.3%) 0 (0%) 4 (5.19%) 
History of CVD   11 (50.0%) 1 (14.3%) 0 (0%) 18 (23.1%) 
Any contraindications d 20 (90.9%) 6 (85.7%) 7 (53.8%) 51 (65.4%) 
Drugs with interactions e 15 (68.2%) 4 (57.1%) 9 (69.2%) 62 (79.5%)  
Age (years) 66.4 (±10.2) 61.0 (±12.1) 65.9 (±10.9) 66.4 (±9.7) 
Age min-max   37-80 37-77 43-80 41-90 
BMI kg/m2 f 26.8 (±5.60) 29.6 (±5.38) 31.6 (±8.8) 28.9 (±6.9) 
eGFR ml/min/1.73 m2 f 80.2 (±26.3) 69.1 (±15.3) 71.9 (±15.3) 75.2 (±17.0) 
eGFR <60 ml/min/1.73 m2 6 (27.3%) 2 (28.6%) 3 (23.1%) 12 (15.4%) 
HbA1c (mmol/mol) f 52.6 (±12.7) 49.6 (±14.4) 57.3 (±11.8) 62.1 (±21.6) 
Diabetes duration  11.5 (±7.7) 10.5 (±3.5) 12.1 (±5.6) 12.5 (±8.7) 
Metformin (g/day) g   1.50 (0.75-2.25) 1.50 (0.25-6.37) 1.50 (0.85-2.00) 1.25 (0.62-2.50) 
Higher dose than SPC h 4 (18.2%) 3 (49.3%) 4 (30.8%)  21 (26.9%)  
  41 
 
Table 7B. Characteristics of individuals with metformin in femoral blood classified as 
intoxications (single substance intoxication (A) + multiple intoxication (B)) or controls 
(controls (C) + cases with another cause of death (O)). All significance tests are two-
tailed. Number of individuals (%), mean (± SD) or median (25th-75th perc). 
 
 
Variables 
 
 
Intoxications (A+B) 
 
 
Controls (C+O) 
 
 
p-value 
Number of cases   29 91  
Metformin median (µg/g)  41.0 (22.5-68.0) 4.10 (1.70-8.40) 0.001* 
Age (years) 65.1 (±10.73) 66.2 (±9.82) 0.88 
Gender (male)  19 (65.5%) 68 (74.7%) 0.348 
In the NDR a  25 (86.2%) 82 (90.1%) 0.732 
Insulin c  14 (48.3%) 34 (37.5) 0.384 
 Sulphonylurea c 10 (34.5%) 31 (34.1%) 1.00 
Living alone 26 (89.8%) 65 (71.4%) 0.050 * 
 Known alcohol abuse  22 (75.9%) 37 (40.8%) 0.001* 
Ongoing infection  6 (20.7%) 15 (16.5%) 0.780 
Dehydration  7 (26.9%) 15 (16.5%) 0.259 
History of CKD  11 (37.9%) 21 (23.1%) 0.148 
History of heart failure   1 (3.45%) 7 (7.69%) 0.678 
History of stroke 5 (17.2%)   4 (4.4%) 0.037* 
History of CVD   12 (41.4%) 18 (19.8%) 0.027 * 
Any contraindication d  26 (89.7%) 58 (63.7%) 0.010 * 
Drugs with interactions e 19 (65.5%) 71 (78.0%) 0.219 
BMI (kg/m2) f 27.4 (±5.59) 29.3 (±7.26) 0.307 
eGFR (ml/min) f 78.0 (±24.67)  74.7 (±16.7) 0.892 
eGFR < 60 (ml/min)  9 (31.0%) 15 (16.5%) 0.111 
HbA1c (mmol/mol) f 52.0 (±12.8) 61.4 (±20.5) 0.018 * 
HbA1c < 52 (mmol/mol) 16 (64.0%) 28 (34.1%) 0.011 * 
Diabetes duration (years) 11.3 (±7.09) 12.4 (±8.31) 0.812 
Dispensed metformin (g/day) g 1.50 (0.75-3.50) 1.25 (0.75-2.50) 0.663 
Higher dose than SPC h 7 (24.1%) 25 (27.5%) 0.813 
 
a) Registered in the NDR 
b) Diagnosed with T2DM versus no confirmed diabetes diagnosis 
c) With dispensed drug from pharmacies during the same period as dispensed metformin 
d) With any contraindications to the use of metformin according to the SPC 
e) With dispensed drugs with risk of interactions with metformin according to SPC 
f) At last healthcare visit, registered in the NDR 
g) Estimated mean dispensed dose of metformin from pharmacies (g/day) last 90 days 
h) Estimated mean dose metformin higher than recommended daily dose in SPC, adjusted 
for kidney function 
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Reference concentrations 
The result shown in Figure 8 demonstrates that the median concentration of metformin in 
single intoxications, group A (48.5 µg/g, range 13.0-210 µg/g) and in multiple intoxications, 
group B (21.0 µg/g, range 4.40-95.0 µg/g) were both significantly (p<0.05) higher compared 
to the median concentration of metformin in controls, group C (2.30 µg/g; range 0.70-21.0 
µg/g). The median blood concentration of metformin in intoxications (A+B) was ten times 
higher than the concentrations in controls (C+O). There was no statistical difference between 
the median concentration of metformin in group C compared with the median in group O 
(4.60 µg/g, range 0.64-54.0 µg/g). 
 
Figure 8. Median post-mortem concentrations (µg/g) of metformin in femoral blood.  
Kruskal-Wallis test, independent samples, pairwise comparison, *p<0.05, **p<0.0 1, ***p<0.001  
 
Risk factors for metformin intoxication 
A greater proportion of intoxications (A+B) than controls (C+O) had one or more of the 
contraindications for the use of metformin (89.7% (n=26) versus 63.7% (n=58, p<0.05). In 
addition, alcohol abuse was a prominent contraindication that was in itself significantly 
associated with fatal intoxication. Other important possible risk factors regarding fatal 
metformin intoxication included living alone, history of cardiovascular disease, stroke and/or 
an HbA1c (<52 mmol/mol). The values for each valued risk factor are presented in Table 7B. 
The median dispensed daily dose of metformin over the last 90 days or the last year did not 
differ between intoxications and controls. Further, several of the deceased had dispensed 
drugs, other than metformin, which indicated increased risk for interactions with metformin, 
but there were no statistical differences between groups. The discrepancies in proportions (%) 
of risk factors between intoxications and controls are presented in Figure 9. 
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Figure 9. Risk factor characteristics, presented as (proportion, %) for intoxications 
(A+B) versus controls (C+O), and group differences evaluated by appropriate test 
statistics. All tests were two-tailed. Number expressed as %, *= p<0.05.  
Abbreviations: cardiovascular arterial disease (CAD) cardiovascular disease (CVD), chronic kidney disease 
(CKD), arterial fibrillation (AF) 
 
9 DISCUSSION 
General  
This doctoral thesis aims to evaluate consequences of inadequate use of GLD in individuals 
with diabetes mellitus and to contribute to a better awareness of risk factors associated with 
these consequences.  
First, this thesis shows several serious consequences associated with inadequate use of 
GLD in a Swedish diabetes population. This thesis suggests that experiences of 
hypoglycaemia, fatal hyperglycaemia and fatal intoxication of metformin are indications of 
consequences of inadequate use of GLD in clinical practice. 
Second, this thesis illustrates different aspects of inadequate use of GLD. We found a 
significant number of individuals with confirmed refill gaps, self-reported non-adherence, 
non-persistence with medicine, and clinical inertia, including prescribing a GLD to patients 
with contraindications to the use of the drug.  
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Third, this thesis presents several identifiable risk factors associated with inadequate use of 
GLD, which is important since non-adherence to medicine is often unknown and the most 
critical first step in improving adherence is recognition of its absence. This thesis highlights 
risk factors associated with inadequate use of GLD such as, for example, poor glycaemic 
control, psychosocial factors, alcohol abuse, experiences of side-effects and living 
alone,which may lead to serious consequences for patients due to inadequate use of GLD. 
There has been extensive research on non-adherence over the past decades. The present thesis 
confirms the recent review that states that non-adherence to GLD remains an essential 
ongoing problem that still needs attention [13]. Similar to the aim of this thesis, the review 
highlights the need for awareness of identifiable and modifiable risk factors associated with 
non-adherence to improve management of T2DM [13].  
This thesis addresses the problems associated with inadequate use of GLD. An appropriate 
use of pharmaceutical drugs is a key factor to the success of a patient’s treatment. 
Consequences associated with inadequate use of GLD  
Poor glycaemic control  
The main finding was that all the studies in this thesis collectively confirm a wide 
discrepancy between recommended HbA1c targets and actual achievements, since almost 
half of the study population in every study had uncontrolled diabetes [67, 68]. The population 
in Study I managed by the primary care centres had good access to healthcare and a variety of 
subsidized GLD but despite this, only 40% of the patients achieved the HbA1c target as 
defined by the national treatment goals [53].  
In Study II, 47% of the deceased showed elevated HbA1c levels (≥75mmol/mol) at the last 
healthcare visit, which doubled the risk for fatal hyperglycaemia. Interestingly, the results 
showed that microvascular disease was also a significant risk factor associated with fatal 
hyperglycaemia which suggests that the deceased most likely had a history of poor glycaemic 
control since microvascular complications are related to long-lasting poor glycaemic control 
[146]. Our findings show a strong association between poor glycaemic control and fatal 
hyperglycaemia in agreement with recent findings that show that a history of poor glycaemic 
control is associated with an increased risk of all-cause mortality in patients with diabetes 
[49]. Further, the results confirm that individuals who died due to hyperglycaemia more often 
showed an inadequate refill adherence of GLD, probably the cause for developing 
hyperglycaemia that caused or contributed to death.  
Hypoglycaemia  
The main finding was that patients with moderate or worse symptoms of hypoglycaemia 
reported poorer adherence to medication than patients with no or mild symptoms. 
Hypoglycaemia has been suggested to be one of the main limiting factors for achieving 
adequate glycaemic control due to the association with poor adherence because of the side-
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effects, particularly among patients treated with SUs [147-149]. Self-reports in Study I 
demonstrated that experiences of hypoglycaemia have a negative impact on both adherence to 
medication and patient satisfaction with treatment. This thesis emphasises the importance of a 
wider understanding of patient-reported experiences and preferences in order to improve the 
management of diabetes mellitus. 
In Study I, one out of five patients was experiencing hypoglycaemic episodes of such severity 
(moderate or worse symptoms) that their daily activities were in some way interrupted due to 
disturbing and worrying symptoms. The proportion of patients who reported any experience 
of hypoglycaemia (34%) was similar to the proportion previously reported in studies of 
patients treated with SUs [147, 148]. However, since there is no consensus on the definition 
of hypoglycaemia in the literature, it is difficult to compare studies on hypoglycaemia. Our 
classification of hypoglycaemic episodes is consistent with the definition used in widely 
recognized reviews on the subject [124, 150]. The finding that patients in Study I who were 
experiencing moderate or worse episodes of hypoglycaemia actually had lower HbA1c than 
those who reported no or mild hypoglycaemia is expected, since hypoglycaemia can be 
considered as a consequence of low HbA1c [151]. But still important because, symptomatic 
hypoglycaemia could need more clinical attention since it is associated with poorer adherence 
to GLD, shorter persistence to GLD and lower quality of life, which may have a negative 
impact on health outcomes in patients with T2DM [6, 79, 122, 152-155].  
The results of Study I suggest that glycaemic control is achieved at the expense of symptoms 
of hypoglycaemia in patients treated with metformin and SU. The T2DM patients walk a fine 
line between glycaemic control and symptoms of hyperglycaemia and worries about 
hypoglycaemia and the consequences seem to refrain both patients and physicians from 
following appropriate treatment recommendations [151, 156-159]. Study I highlight the 
importance of PROM to identify symptoms of hypoglycaemia and dissatisfaction with 
treatment to personalize the treatment regimens to improve management of type 2 diabetes. 
Fatal Hyperglycaemia 
The main discovery in Study II was that individuals with fatal hyperglycaemia were more 
likely to have poor refill adherence of GLD versus living controls, which probably was the 
reason for developing a fatal hyperglycaemia. Actually, 26% of the cases had not refilled any 
GLD over the 3 months prior to death. The results were confirmed by police who reported 
that there was no GLD found at the scene in almost half of the cases (47%).  
During the study period we identified 322 cases with fatal hyperglycaemia with elevated 
vitreous glucose levels with a mean concentration of 39.5 ±19.4 mmol/L. The results indicate 
life-threatening levels of blood glucose at the time of death since a vitreous glucose level of 
10 mmol/L mmol/L is equivalent to about 26 mmol/L in blood, and the majority of cases had 
far higher levels [134, 160]. 
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We believe that fatal hyperglycaemia is overlooked if vitreous glucose is only analysed upon 
suspicion, and suggest that this analysis should be performed in all autopsy cases [73, 161]. 
The observations in Study II as well as those reported by Zilg et al [133] are important for 
practitioners to be aware of. 
Metformin intoxication  
The main finding was that metformin in most cases was prescribed to patients despite 
contraindications, warnings or precautions to metformin use, including renal dysfunction and 
alcohol abuse. The prevalence of alcohol and medication interactions is widespread but could 
need some more attention in clinical praxis to improve the appropriate use of medicine [162, 
163]. Further, fatal and non-fatal concentrations of metformin in postmortem femoral blood 
were established. The median concentration of metformin in postmortem femoral blood in 
intoxications was significantly higher than the median level of metformin in controls. 
However, the metformin concentration varied from 13-210 µg/g in single intoxications. The 
result confirms previous case reports and postmortem studies with a similar range of 
metformin concentration in individuals who died due to metformin poisoning [164, 165].  
The comprehensive information from police reports and the NFMD was enriched with robust 
information regarding the history of comorbidity, dispensed pharmaceuticals and diabetes 
health-related variables from the linked registries. The fatal and non-fatal reference 
concentrations reported in Study III will hopefully be helpful in cases where for evaluation of 
cases where the circumstances surrounding death are unclear. Given that the study cohort is 
very well characterised and fairly large, it seems reasonable to suggest intoxication with 
metformin as a cause of death when the postmortem femoral blood level exceeds 10 µg/mL. 
Undiagnosed diabetes  
We found 48 (15%) individuals with confirmed fatal hyperglycaemia, who were undiagnosed 
and had no evidence of dispensed GLD. Most of these individuals (85%) were older than 45 
years of age and most likely individuals with undiagnosed T2DM. The result confirms 
previous estimates that many individuals with T2DM are probably undiagnosed and suggests 
that Sweden may have a noteworthy number of adults with unknown T2DM, and that death 
in diabetic coma could be the first manifestation of diabetes [20, 166]. The presented risk 
factors may be helpful for health care providers to decide to perform physical examinations, 
including blood glucose analysis, to identify individuals with undiagnosed diabetes. 
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Inadequate use of GLD 
Non-adherence 
The main outcome in Study I was the significantly negative association with adherence and 
severity of the experienced hypoglycaemic symptoms. Further, patients with moderate or 
worse symptoms of hypoglycaemia reported poorer adherence to medication, more barriers to 
adherence to medicine and also reduced treatment satisfaction than patients with no or mild 
symptoms. This thesis suggests that healthcare providers should consider PROM to identify 
non-adherence and improve the management of diabetes mellitus in clinical practice. 
Study I showed that the mean HbA1c was lower in the group of patients with worse 
symptoms versus the group with no or mild symptoms even if they reported better adherence. 
However, with the variety of methods and lack of definition of adherence, results should be 
compared with some caution. Notably, others have demonstrated that the relationship with 
non-adherence and uncontrolled diabetes occurs more frequently in studies measuring 
adherence via refill adherence than self-report measures [161, 167, 168]. A possible weakness 
with Study I may be that self-reports tend to overestimate adherence. To minimise the risk of 
overestimation we dichotomized adherence and turned the focus onto detecting non-
adherence, since self-reports of non-adherence usually are reliable, “a patient who admits to 
poor adherence is generally being candid” [72]. However, the proportion of non-adherent 
patients may have been underestimated, even if self-report adherence measures most likely 
provide good specificity and weak sensitivity for detecting poor adherence [126, 169].  
The main finding in Study II was that a larger proportion of individuals who died due to 
hyperglycaemia had inadequate refill adherence of GLD compared to living controls, which 
confirms that non-adherence is most likely one of the primary reasons for hyperglycaemic 
events. Moreover, since non-adherence is a common problem among a general population 
with diabetes mellitus, it is reasonable to believe that the magnitude of non-adherence to 
medicine or inadequate use of GLD may be even higher among patients with identified poor 
glycaemic control [170]. Therefore, this study suggests a need for clinical attention to poor 
glycaemic control and improved skills to evaluate adherence as well as appropriateness of 
treatment in the clinical setting. 
Clinical inertia 
In Study I the result showed no differences in glycaemic control when comparing the 
adherent group with the non-adherent group which made us aware that adherence to 
medication only makes sense if a suitable dose of an effective and safe regimen of GLD is 
prescribed [171, 172].  
Accordingly, this thesis suggests a wider approach to non-adherence and a preference for the 
wording “inadequate use” since both a patient’s behaviour and a physician’s clinical inertia 
represent key obstacles to adequate use of GLD. Optimal adherence is crucial for the success 
of a patient’s treatment and most studies show that adherence to GLD is associated with 
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better glycaemic control in clinical practice [7, 139]. The result in Study I was unexpected but 
even more important since it showed that we should not put all the focus or responsibility on 
the patient to adhere to medicine without evidence that an appropriate medicine with an 
adequate dose was prescribed. It has been reported that clinical inertia, including inadequate 
prescribing, seems to be even more common than non-adherence to GLD in patients with 
poorly controlled diabetes [173]. In line with this, others have claimed that non-adherence 
contributes to poor glycaemic control in patients with diabetes mellitus in Sweden, but this is 
probably not the only reason since about 90% had satisfactory refill adherence in a general 
population with T2DM treated with oral GLD [174].  
Alternatively, therapeutic decisions could be based on unreliable assumptions of adherence, 
which may lead to an increase of doses or adding another GLD due to poor glycaemic 
control, which may lead to severe consequences. 
Poor glycaemic control in patients treated with GLD should lead to a comprehensive review 
of the situation to find the most reasonable explanation, including non-adherence, poor 
efficacy of medicine, inadequate doses, interactions, contraindications or other prescription 
error, to improve HbA1c target achievement and patient satisfaction.  
Study III shows that the metformin intoxication was confirmed to be intentional only in eight 
cases (23%). Therefore, it is crucial to remember in the postmortem context that high drug 
concentrations may not always be due to an acute high intake but could result from 
accumulation of metformin due to impaired elimination. Ultimately, we should not 
exclusively focus on the patient's responsibility to minimise the risk of stigmatisation of 
intoxicated patients. 
It is well known that treatment with metformin is considered to be contraindicated in 
individuals with acute or chronic conditions that may cause lactic acidosis such as renal 
dysfunction, infections, dehydration, trauma, heart failure, myocardial infarction, liver 
insufficiency, advanced age or alcohol abuse [13, 39]. However, in Study III the most 
common precipitating factor in single intoxications was any contraindication (90.9%) 
quantified as: chronic or acute alcohol abuse (77.3%), renal dysfunction (40.9%), severe 
ongoing infection (27.7%) or dehydration (31.6%). In addition, 68% of intoxications were 
simultaneously treated with prescribed pharmaceuticals with increased risk of interactions 
with metformin.  
However, metformin is extensively used since the drug offers effective glycaemic control and 
additional effects that contributes to significant clinical improvement. A large Swedish study 
showed that individuals with T2DM treated with metformin were at lower risk of death than 
those with insulin or other oral treatments [175]. Further, the study showed that metformin 
lowered the risk of severe outcomes also in individuals with T2DM and renal dysfunction 
[175]. The results of the latter study have contributed to the recent revision of the metformin 
treatment in patients with renal dysfunction. The benefits of metformin seem to outweigh 
most of the risks of the treatment. However, from what we know there is little information 
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regarding treatment with metformin in patients with other contraindications and warnings to 
the use of metformin than renal dysfunction. The high proportion of subjects with alcohol 
abuse observed in these studies warrants attention, even if the cohort is biased by the select 
cases that are subjected to a forensic autopsy. 
Risk factors associated with inadequate use of GLD  
This thesis has identified several contributing risk factors associated with consequences of 
inadequate use of GLD. 
First, Study I demonstrates that experiences of side-effects such as hypoglycaemia could be 
considered as a risk factor since such experiences may have a negative influence on 
adherence to medications and a negative impact on patient satisfaction with treatment. 
Hypoglycaemia may not only be a risk factor, but also be a consequence of inadequate use of 
GLD.  
Second, Study II showed that the risk of death due to fatal hyperglycaemia was higher among 
individuals treated with insulin compared to those treated with oral anti-diabetic drugs. In 
addition, Study II showed that poor glycaemic control and elevated HbA1c values were 
strong risk factors for fatal hyperglycaemia, an acute event caused by uncontrolled diabetes. 
In most cases, the reason for developing fatal hyperglycaemia was probably the poor refill 
adherence of GLD.  
In addition, Study II confirms an association between non-adherence and psychosocial 
factors, previously reported [101-104, 161, 176, 177]. The risk of fatal hyperglycaemia was 
significantly increased in patients living in a single household, and/or who had a history of 
psychiatric illness or with evidence of substance abuse. For this reason, the understanding of 
a patient’s psychosocial status in clinical practice may be equally important as other more 
traditional and well-known risk factors when improving the management of T2DM patients.  
Third, Study III shows a high correlation between fatal metformin intoxication and alcohol 
abuse (75.9%). This is an interesting observation since older adults frequently use 
pharmaceuticals that may interact with alcohol and lead to undesired effects [40]. It has been 
reported that alcohol abuse and its effects seem to be associated with hypoglycaemia and/or 
lactic acidosis in diabetic patients treated with metformin [40, 41]. The results suggest that 
clinicians should consider monitoring the alcohol consumption and inform patients who are 
prescribed alcohol-interactive drugs about the risk of undesired effects to minimise the risk of 
metformin intoxications. Hence, healthcare providers should be aware of the potentially 
serious effects of metformin when prescribed to patients with alcohol abuse or other 
contraindications. However, our results should be interpreted with caution considering the 
select population and the possible presence of confounders among these subjects [178, 179]. 
Finally, poor glycaemic control was frequently observed in all three studies and has been 
recognized as a common consequence of non-adherence or inadequate use of GLD. 
Uncontrolled diabetes in general could be considered a key risk factor; it is easy to identify 
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and is significantly associated with non-adherence and other forms of inadequate use of GLD 
[7, 180-182].  
Strengths and limitations 
A general limitation applicable for all the studies is that we have no information about to 
what extent the patients actually used their medication, since it cannot be proven that the 
patients took the medication after it was dispensed from the pharmacy. Further, we have no 
information on how the physicians in fact prescribed the medicine; we could only evaluate 
dispense patterns.  
A major strength of data collected from registries as a source of data for research is that they 
mirror clinical practice and are free from the recall bias that may be seen in data collected 
through patient surveys. One of the strengths of the two studies based on the NFMD is that 
the study populations are very well characterised because of the linkage with other registries. 
To link registries could boost results when data from independent sources confirm each 
other’s findings. From the NFMD we collected information that showed that the police found 
no GLD medicine at the death scene in most (>50%) of the cases. This information confirms 
the data retrieved from the SPDR that a large proportion of individuals who died due to fatal 
hyperglycaemia had no or very poor refill adherence of GLD. 
However, the fact that data collected from registries reflect clinical practice may also be a 
potential weakness. Since data are not recorded for research purposes or according to a strict 
protocol, values for variables such as HbA1c are only available whenever these tests were 
conducted in clinical practice and not at systematic intervals as in clinical trials. 
As mentioned before, it is difficult to estimate the actual intake of medicine. There was no 
evidence that intoxications had dispensed more than maximal daily doses of metformin from 
pharmacies, but that does not exclude an acute high intake.  
The routines for analysis of vitreous glucose and metformin upon suspicion of diabetic coma 
and metformin intoxication, respectively, imply that it is likely that some cases may go 
undetected. This selection bias in Study II and III to include cases with specific case 
circumstances probably means that the numbers of diabetic coma and metformin 
intoxications are underestimated. Another overall limitation may be that the cohorts that 
underwent forensic autopsy may not be entirely representative of all individuals at risk of 
metformin intoxications or fatal hyperglycaemia which may limit extrapolation of our results. 
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10 ETHICS 
General  
The aim of the thesis was to contribute to a deeper understanding of inadequate use of GLD 
and identify risk factors. However, we need to do this with caution, since some of the pre-
defined variables, e.g. substance abuse, mental disorder or living alone could be associated 
with indignity. More importantly, in order to minimise the risk of stigmatisation of patients 
with chronic diseases, we should not put all the responsibility on the patient to succeed with 
treatment.  
Study I included patients who were recruited by approved investigators between January 
2009 and August 2009. After having given consent to participate in the study, patients filled 
out questionnaires. Data on patient characteristics and medical record data were logged into 
an online form by healthcare providers. Investigators also completed a web-based case report 
form on laboratory values, medical history and GLD. The patients in the study did not 
undergo any intervention since they were treated according to clinical practice. Therefore, we 
expected no increased risks or extraordinary benefit for patients participating in the study. A 
database was formed for compiling questionnaire and patient records data using anonymous 
patient numbers. Patients’ questionnaire data were entered into the database and analysed at 
group levels. The study protocol was approved by the Regional Ethics Review Board in 
Linköping (Dnr M185-08). 
In Study II and III the forensic pathology findings and forensic toxicology results in the 
NFMD were retrieved for each cohort. The unique PIN was used to link data in the NFMD 
with population-based Swedish databases. Typically the ethical review boards in Sweden will 
waive informed consent when using data from national registries for research, which as also 
was true for our studies. Nevertheless, there are rigorous restrictions as to how and when the 
retrieved information can be used. We believe that the research benefits both patients and 
society, and that informed consent should not be required for large-scale medical research. 
Collecting informed consent could have reduced the statistical power and the costs of 
obtaining the consent from the controls (the cases were not alive) would be unreasonably 
large and prohibit this research. The pros and cons with the PIN and registry-based health 
data with no required informed consent have been discussed in-depth previously [113]. In our 
study the linkage procedure was performed at the NBHW where the PIN was replaced with a 
serial number to ensure anonymity. The collected data were handled safely, not shared with 
others and data will be destroyed once the evaluation has been completed or when it is no 
longer needed for the project. Our aim was to ensure patient data protection and 
confidentiality in agreement with the guidelines for Good Practice in Data Privacy, Medical 
Record Confidentiality, and Research developed by the International Society for 
Pharmacoepidemiology (ISPE). However, some of the pre-defined variables, e.g. substance 
abuse, mental disorder or living alone, could be associated with stigma. The aim of the thesis 
was to identify risk factors for non-adherence; and the data have been handled with caution in 
order to avoid stigmatisation and avoid putting all the responsibility on the patient. Study II 
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and III were approved by the Regional Ethics Review Board in Linköping, Sweden; study II: 
Dnr 2014/11-31 and study III: 2012/343-31 and 2017/328-32. 
Ethical considerations of adherence 
In medicine and in Swedish healthcare there are four well-established central principles of 
medical ethics. Ethical discussions are frequently based on these four basic principles which 
were described by Beauchamp and Childress [183]. They should also be considered when it 
comes to adherence to treatment. 
• The principle of goodness  
• The principle of no harm 
• The principle of justice  
• The principle of autonomy 
 
The principle of goodness and the principle of no harm are important, since adherence will 
only benefit the patient if the patient initially has been prescribed an adequate treatment 
regimen. It is important that drugs are thoroughly tested in order to protect patient safety 
since the treatment should do more good than harm. There is no clear hierarchy between 
these principles. However, when comparing them, some treatments may be ethically correct 
in one case but not in another. The principle of justice is that everyone should be cared for 
equally, which can be an issue if healthcare providers offer adherence support selectively to 
some subpopulations. On the other hand, it could be fair to offer adherence support to patients 
who need it the most. The principle of autonomy is obvious, in that a patient cannot be forced 
to be adherent if the patient actively chooses to be non-adherent or chooses to discontinue the 
treatment. The communication and collaborative relationship between the diseased and the 
healthcare provider seems to be very central to making adherence to treatment successful.  
Non-adherence to medication is a common problem in healthcare and presents a major barrier 
to safe, efficient, and effective healthcare delivery. Therefore, it is important to recognise 
potential risk factors for non-adherence and discuss the ethical and medico-legal problems. 
Further research is warranted regarding potential solutions to this common problem. 
Does a history of non-adherence disqualify individuals for some treatments or could it be 
used as a diagnostic tool to identify individuals that could benefit from some other treatment 
regimens or support programs? 
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11 CONCLUSIONS 
11.1 GENERAL  
The consequences of inadequate use of GLD in individuals with diabetes mellitus in Sweden 
are multifaceted. Patients who do not adhere to medication may demonstrate therapeutic 
failure, experience side-effects, and even result in premature death. 
The results in this thesis reveal generally poor glycaemic control in clinical practice in 
Sweden. Poor glycaemic control is an obvious consequence of inadequate use of GLDs. This 
thesis indicates that both patient behaviour and the physician’s clinical inertia represent 
crucial barriers to adequate use of glucose-lowering drugs. Our findings suggest there is a 
need for strategies to detect inadequate use of medication, since non-adherence usually 
remains unseen. The results also highlight the need for improving adherence to prescribed 
drugs as well as ensure appropriate prescription of GLD in patients with diabetes. 
Overall, the studies indicate that patients with risk factors such as experiences of side-effects, 
poor refill adherence, and living alone, contraindications for the medicine or with substance 
abuse seem to be vulnerable groups at increased risk of negative consequences due to 
inadequate use of GLD.  
By linking data from the NFMD with national registries, we generated unique data which 
were supplemented with information from autopsy reports and police reports, and medical 
charts, when available, thus allowing for a detailed phenotyping that is not possible to 
generate from the national registries in isolation. This approach was the basis for the 
identification of consequences of, and risk factors for, inadequate use of GLD. The results 
may be used in the preventative work to reduce premature death in persons with diabetes.  
11.2 THE SPECIFIC STUDIES IN THIS THESIS 
Study I 
Symptoms of hypoglycaemia in individuals with T2DM were significantly associated with 
non-adherence to GLD and with lower scores for patient satisfaction with the GLDs and more 
barriers for adherence, even with lower mean HbA1c values.  
The overall HbA1c goal achievement was poor and there were no differences between the 
adherent and the non-adherent groups, demonstrating the challenge to achieve glycaemic 
control without symptoms of hyperglycaemia.  
Study II  
This study identified several significant risk factors for fatal hyperglycaemia such as insulin 
treatment, poor glycaemic control, inadequate refill adherence, history of microvascular 
disease, history of psychiatric illness, substance abuse and living alone. Identified groups 
could benefit from special attention by clinicians to improve adherence and glycaemic control 
to reduce the rate of serious hyperglycaemia. 
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In addition, the results showed that there were a significant number of individuals with 
undiagnosed diabetes where fatal hyperglycaemia obviously was the first manifestation of the 
disease, in most cases probably representing a recently developed diabetes, which went 
undetected because the patient did not seek help, or because suspicion of diabetes were not 
raised by the symptoms that the patient described upon health care visits. Tests for diabetes 
are readily available and easy to carry out; these studies suggest that such testing be done 
more liberally. 
Study III  
This study showed that elevated drug concentrations may not only be due to an acute high 
intake but may result from accumulation of metformin due to impaired elimination. Most of 
the intoxicated subjects had one or more contraindications for the use of metformin 
suggesting that patients’ behaviour and physicians’ prescription pattern may both contribute 
to inadequate use of metformin.  
The revealed evidence may lead to more careful administration of metformin to minimize 
risks in patients with identified risk factors particularly where safer alternative exist. 
In Study III we also provide fatal and non-fatal postmortem femoral blood reference 
concentrations of metformin that is expected to be useful in the evaluation of suspected fatal 
intoxications, and in obscure cases. The results suggest that metformin intoxication could be 
considered to be the cause of death when the postmortem femoral blood concentrations 
exceed 10 microgram/mL.  
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12 CLINICAL IMPLICATIONS AND FUTURE STUDIES 
 
As the prevalence and complexity of diabetes mellitus increase with population ageing, the 
demography in Sweden indicates that the role of overall adequate use of medicine, including 
adherence to medicine and evidence-based prescribing is likely to gain even more 
importance.  
Non-adherence to medication could be considered as a condition that can be modified. 
However, most healthcare providers are not trained to recognise or handle medication non-
adherence. This thesis provides relevant information to healthcare providers that can be used 
to identify subgroups that may be at risk of serious non-adherence to GLD. The health care 
systems need to intensify their effort in informing physicians, pharmacists as well as patients 
to recognise inadequate use of medicine in order to diminish the risk of serious consequences 
due to inadequate use of GLD. We may also develop and improve tools that facilitate the 
early detection of inadequate use of medicine by using the pharmacy records and the 
pharmacists, as dispensers of medicines, as a more prominent role in the future to improve 
effectiveness of treatment.  
Further, the thesis may provide information considered useful for identifying subgroups for 
targeted actions of future intervention studies, with customised adherence programmes to 
increase adherence to GLD and improve glycaemic control. In recent years, electronic 
collection of PROM has become more realistic which may assist the clarification of 
symptoms, side-effects, and barriers to adherence to medicine to improve the identification of 
inadequate use of GLD. Further research and implementing strategies of adherence 
programmes as well as PROMs in clinical practice are warranted.   
Future research may focus on decision support tools but also PROMs to adjust the 
prescription routines and ensure an optimisation of appropriate and effective treatment 
matched with each patient’s preferences for better health outcomes in patients with diabetes 
mellitus.  
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